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[571 ABSTRACT 
Methods of forming multi-lamellar microcapsules having 
alternating layers of hydrophilic and hydrophobic immis- 
cible liquid phases have been developed using different 
polymerlsolvent systems. The methods use liquid-liquid 
diffusion and simultaneous lateral phase separation, con- 
trolled by proper timed-sequence exposures of immiscible 
phases and low shear mixing, to form narrow size distribu- 
tions of spherical, multilamellar microcapsules. The use of 
special formulations of solubilized drugs, surfactants, and 
polymeric co-surfactants in aqueous vehicles which are 
dispersed in hydrocarbon solvents containing small quanti- 
ties of oil, low molecular weight co-surfactants and glycer- 
ides that are aqueous insoluble enables the formation of 
unique microcapsules which can carry large amounts of 
pharmaceuticals in both aqueous and non-aqueous solvent 
compartments. The liquid microcapsules are quickly formed 
in a single step and can include a polymeric outer “skin” 
which protects the microcapsules during physical manipu- 
lation or exposure to high shear forces. Water-in-oil and 
oil-in-water microcapsules have been formed both in lxg 
and in microgravity, which contain several types of drugs 
co-encapsulated within different fluid compartments inside 
the same microcapsule. Large, spherical multi-lamellar 
microcapsules have been formed including a cytotoxic drug 
co-encapsulated with a radiocontrast medium which has 
advantages for chemoembolization of vascular tumors. In 
certain cases, crystals of the drug form inside the microcap- 
sules providing zero-order and first order, sustained drug 
release kine tics. 
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MICROCAPSULES AND METHODS FOR 
MAKING 
ORIGIN OF THE INVENTION 
therefore, have very low encapsulation efficiencies. Certain 
liposomal drug formulations, including anti-tumor lipo- 
somes containing dexorubicin [Gabizion et al. 19921 or 
muramyltripeptide have been studied extensively in clinical 
Microcapsule formation by liquid-liquid dispersion of 
aqueous drugs and organic solvents typically produces 
is removal of the organic solvent (typically evaporated) to 
form reverse-phase evaporation vesicles (rev) or stable 
plurilamellar vesicles (splv). 
A. Field of the Invention Spherical multilamellar vesicles (mlv) are rarely formed 
The invention relates to methods for  making by these methods and the size distribution is quite hetero- 
microcapsu~es, encapsulating pharmaceutical compounds in geneous. in Order to generate multilamellar 
vesicles, film casting with organic solvents, hydration and microcapsules, microcapsules, microcapsule encapsulated IS 
pharmaceutical compositions and products, and of sizing through inert membrane is 
required [Talsma and Crommelin 19921. Methods of form- using the same. 
ing multi-layered microcapsules often require emulsification 
of the aqueous phase into organic carrier solutions by shear, B. Description of the Related Art 
Many CYtotoxic Or bioactive drugs and enzymes cannot be 2o bubbling or sonication. Sophisticated, multi-step emulsion 
injected intravenously. Others can be injected, but are rap- technology is required and yields of uniform type and size 
idly degraded before they reach the target tissue. Still others are often very low, 
that their biological half-life is too short to be of therapeutic delivery systems, especially for drugs that are poorly soluble 
value. Still other drugs are insoluble in aqueous solutions. in aqueous carriers, A microemu~sion typically contains 
Since intravenous injection in hydrocarbon solvents is not 2s droplets in the range of o,l-lp in diameter, Such micro- 
well tolerated by patients, such drugs are difficult to admin- emulsions are characterized by very fluid and dynamic 
ister. micelles which are formed by sequential mixing one immis- 
One method for overcoming these limitations is encap- cible phase with another using surfactants and co-surfactants 
Sulation into microcaPsules Or 1iPosomes. Encapsulation of 3o [Bhargava et al. 19871. Typically, surfactants that produce 
drugs or biological therapeutics into liposomes or liquid water-in-oil (w/o) microemulsions have a hydrophilic- 
microcapsules can enable delivery to target organs where the lipophilic balance (HLB) rating of 3 to 6, while those that 
bioactive drug can be released directly by diffusion. Properly produce oil-in-water (OW) microemulsions have an HLB of 
designed microcaPs~les can Provide unique methods of 8 to 18. The surfactants can be non-ionic, ionic, or ampho- 
direct delivery by parenteral injection, nasal inhalation and 3s teric, Often, medium chain-length alcohols are added as the 
dermal administration for sustained release of important co-surfactant in the last step in achieving the final micro- 
bioactive drugs. emulsion. 
The size and shape of the microcapsules is critical for the The major disadvantages of microemulsions is that each 
distribution and drug delivery in the tissues. Typically, micelle (liquid capsule) is too small (typically, less than 1.0 
microcapsules of 1-20 micron diameter are optimum for 40 micron) for deposition in larger vascular beds when admin- 
intravenous administration, whereas, 50-300 micron diam- istered by intravascular injection. Therefore, microemul- 
eter microcapsules are used for intraarterial delivery and 300 sions are not suitable for chemoembolization type treatment 
micron or greater for intraperitoneal administration. In each of vascularized tumors. Additionally, since microemulsions 
5 trials. 
The invention described herein may be manufactured and 
by Or for the Government Of the United States Of 
America for governmental purposes without the payment Of water-in-oil (W/O) type liposomes. A second requisite step 
any royalties thereon or therefor. 
BACKGROUND OF THE INVENTION 
. . 
are cleared from the blood by the liver or kidneys so quickly Liquid microemulsions also have been developed as drug 
size range, highly uniform microspheres are needed for are true colloidal suspensions, they cannot be scaled up to 
maximum packing densities and maximum drug payload 4s large enough size for many intravascular drug delivery 
delivery to target organs or tumors. applications. Microemulsions formed with lipid soluble anti- 
Major difficulties with commercial preparation of micro- tumor agents and low density lipoproteins (LDLS) have 
spheres arise when density-driven phase separation of the been used to target drugs to neoplastic cells that require large 
immiscible carrier fluids occurs. This is especially true when amounts of cholesterol for synthesis of cell membranes 
the microcapsules are constructed by forming waterioil 50 [Halbert et al. 19841. However, LDLs also attract phago- 
emulsions or when attempts are made to encapsulate mul- cytes making the amount of drug actually delivered to the 
tiple drugs. This limits the yield and often results in micro- tumors and thence the therapeutic dose difficult to deter- 
particles that are not spherical nor uniform in size. Non- mine. 
conformity limits the packing density (and, thereby, the drug The use of solid matrix microspheres containing adsorbed 
payload delivered) when the microcapsules arrive at the 5s drugs within the matrix is also known. For instance, U.S. 
target tissues. Pat. No. 4,492,720 to Mosier disclosed methods for making 
Certain current methods of forming microcapsules (such microspheres to deliver chemotherapeutic drugs (including 
as liposomes) are based on chemical characteristics of Cis-Platinum) to vascularized tumors. This method of pre- 
dispersed in an excess of water. Most liposomes carry 60 tion and solid-phase entrapment wherein the water-soluble 
Drugs that are insoluble or that have only limited solubility involves dissolving the aqueous drug and the matrix material 
in aqueous solvents pose problems for incorporating into in a organic solvent, in which they are mutually soluble, then 
liposomes. Such organic-soluble drugs are usually limited in dispersing this mixture in a second organic solvent to form 
liposomal formulations to those that bind inside the hydro- 65 an emulsion that is stable enough for intravascular injection. 
phobic region of the liposome bilayer. Some drugs are so Other approaches have utilized copolymers such as poly- 
insoluble that they do not associate with the bilayer and, vinyl chlorideiacrylonitrile dissolved initially in organic 
certain phospholipids that self-assemble into bilayers when 
pharmaceuticals dissolved in the entrapped water phase. 
paring microspheres is accomplished by liquid encapsula- 
drug is dispersed in a solid matrix material. The method 
5,827,531 
3 4 
solvents to form microparticles containing, for instance other modifications of lipids (i.e., neutral glycolipids) may 
aqueous enzyme solutions. U.S. Pat. No. 3,639,306 to Stern- be affected in order to produce anti-viral formulations. U.S. 
berg et al. discloses a method of making anisotropic polymer Pat. No. 5,192,551 to Willoughby et al. 1993. However, new 
Particles having a SPonge-lke inner support structure corn- types of liposomes and microcapsules are needed to exploit 
Prising large and small void spaces and an outer, s the various unique applications of this type of drug delivery. 
microporous polymer film barrier. A multiple-step batch It is known that microgravity can be advantageously process is used which entails removal of the organic solvents utilized to induce and maintain crystal growth due to the lack used to dissolve the polymers prior to addition of aqueous of density driven convective flow in liquids. U.S. Pat. No. components. Solid-matrix microspheres, however, are often 4,909,933 to Carter et al. discloses an apparatus for carrying not perfect spheres thereby limiting the packing density. 
10 out crystallization of proteins and chemical syntheses by Additionally, many drugs cannot be trapped or adsorbed in liquid-liquid diffusion in microgravity environments. The these systems at effective concentrations and drug-release apparatus comprises a housing having a plurality of cham- rates are often not constant. bers and a valve which separates at least two of the chambers 
Conventional methods of forming of multi-lamellar, so as to allow controlled fluid flow, 
immiscible, liquid microcapsules are limited, because of 1~ 
density-driven phase separation and stratification into hori- 
zontal layers resulting in the necessity to use multi-step, 
The disadvantages Of liposomes Or micro- 
manufacturing methods that require many capsules 
batch processing including mechanical mixing and solvent 
evaporation phases [Talsma and Crommelin 19921, Each 
Conventional methods do not permit simultaneous forma- 2o cologic efficacy 
batch process steps to: '1 form the liposomes, 2, remove 
unwanted Organic detergents, and 3, harvest the 
batch step suffers losses which reduce overall 
tion of the outer skin as the microcapsule itself is formed, 
proper size and shape microparticles for Optimum pharma- 
ventional liposomes often use natural lipids and lectins 
and Crommelin 19921. con- 
Many conventional therapeutic microspheres have natural (from eggs, soybeans and Other inexpensive sources) which 
phospho~ipid outer skins (usually in with tho- attract phagocytic immune that remove the 
lesterol and a fatty amine) and therefore are subject to 25 liposomes from the system before they arrive at 
elimination by immune cells, Other conventional methods the target tissue. This creates variable dose-responses mak- 
use sialic acid and other coatings on the lipid bilayer to mask ing calculations of pharmacokinetics and therapeutic doses 
the body, Without an adequate outer skin, microcapsules cial preparation of microcapsules often involves density- 
driven phase separation of the immiscible carrier fluids, esp. often coalesce thereby reducing shelf-life. 
For instance, U.S. Pat. No. 4,855,090 to Wallach, dis- 
closes a method of making a multilamellar lipid vesicle by These drawbacks limit the yield, make it difficult to 
blending an aqueous phase and a nonaqueous lipophilic harvest the proper size particle, and often result in micro- 
phase using a high shear producing apparatus, me lipophilic particles that are not spherical nor uniform in size, thereby 
point of the lipid components) and is combined with an when the microcapsules arrive at the arterioles or capillaries 
of the aqueous phase, which is also maintained at a in the target issues. Liposomes have a bilayer outer mem- 
the liposomes from detection by the scavenging systems of very 1988i. Major with commer- 
30 when forming waterioil systems. 
phase is maintained at a high temperature (above the melting 35 limiting the Packing density (and drug Payload delivered) 
high temperature. U.S. Pat. No. 5,032,457 to Wallach dis- 
closes a paucilamellar lipid vesicle and method of making 
paucilamellar lipid vesicles (PLV). The method comprises 40 diffuse. This limits the type Of drugs that can be 
brane which requires that the entrapped drug must be 
in both the aqueous and lipid Phases in order to outwardly 
combining a nonaqueous lipophilic phase with an aqueous from conventional liposomes and the mole ratio of aqueous 
phase at high temperatures and high shear mixing to lipid phases limits the amount of drug which can be 
conditions, wherein the PLVs are rapidly formed in a single 
step process. Processes are needed for forming spherical multi-lamellar 
U.S. Pat. No. 4,501,728 to Geho et al. discloses the 45 microcaPsules having alternating hydrophilic andhYdrOPh0- 
encapsulation of one or more drugs or other substances bic liquid layers, surrounded by flexible, semi-permeable 
within a ~iposome covered with a sialic acid residue for hydrophobic or hydrophilic outer membranes which can be 
masking the surface of the membrane from scavenging cells tailored specifically to control the diffusion rate. In 
of the body utilizing techniques known for the production of Particular, methods of making such microcaPsules are 
liposomes. In one embodiment, additional tissue specific SO needed which do not rely on batch Processes involving 
constituents are added to the surface of the ~iposome which density-driven phase separation and stratification into hori- 
cause the liposome thusly treated to be attracted to specific zontal layers, mechanical mixing and solvent evaporation 
tissues. Similarly, U.S. Pat. No. 5,013,556 to Woodle et al. Phases. Moreover, there is clearly a need for methods and 
provided methods for making ~iposomes with enhanced compositions which allow for uniform size and more spheri- 
circulation times. Liposomes created by this method contain ss cal microcaPsules. Such improved microcaPsules would be 
1-20 mole% of an amphipathic lipid derivatized with a particularly useful in the delivery of pharmaceutical com- 
polyalkylether (such as phosphatidyl ethanolamine deriva- Positions. 
tized with polyethyleneglycol). U.S. Pat. No. 5,225,212 to 
Martin et al. discloses a liposome composition for extended 
release of a therapeutic compound into the bloodstream, the 60 Processes and compositions are provided by the present 
liposomes being composed of vesicle-forming lipids deriva- invention which overcome certain of the limitations of prior 
tized with a hydrophilic polymer, wherein the liposome methodology for forming microcapsules. In particular, 
composition is used for extending the period of release of a methods and compositions are provided which form multi- 
therapeutic compound such as a polypeptide, injected within lamellar microcapsules having alternating hydrophilic and 
the body. Formulations of "stealth" liposomes have been 65 hydrophobic liquid layers, surrounded by flexible, semi- 
made with lipids that are less detectable by immune cells in permeable hydrophobic, outer membranes which can be 
an attempt to avoid phagocytosis [Allen et al. 19921. Still tailored specifically to control the diffusion rate. In 
SUMMARY OF THE INVENTION 
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particular, the methods of making microcapsules provided 
by the present invention do not rely on batch processes such 
as density-driven phase separation and stratification into 
horizontal layers, mechanical mixing or solvent evaporation. 
Encapsulation of cytotoxic or labile drugs in such micro- 
capsules enables targeted delivery and sustained release 
kinetics that are not currently available with intravenous 
injection. 
The invention provides, in one aspect, methods of making 
a multi-layered microcapsule. The term microsphere as used 
herein is a general term which can include any spherical 
microscopic vesicle including microspheres, micelles, 
inverted micelles, bilayer vesicles and liposomes. The term 
microcapsule as used herein is a more specific term which 
refers to a microsphere which comprises at least two layers, 
one of which is innermost and is substantially completely 
enclosed within the other. In a distinct break from traditional 
methods for making microcapsules, the methods of the 
invention rely on low shear mixing and liquid-liquid difh- 
sion process, particularly as developed for forming micro- 
capsules that may contain both aqueous and hydrocarbon 
soluble drugs. 
The terms multi-layered and multi-lamellar are used inter- 
changeably throughout the specification and claims and both 
refer to the fact that the microcapsules of the invention 
comprise at least two immiscible layers nested around one 
another. In some instances, the core layer will be hydropho- 
bic in nature and will be completely surrounded by at least 
one neighboring hydrophilic layer. In others, the core layer 
will be hydrophilic in nature and will be completely sur- 
rounded by at least one neighboring hydrophobic layer. 
The basic method of the invention relies on liquid-liquid 
interactions. In the basic method, the first step entails 
formulating a first phase or layer while the second step 
entails formulating a second phase or layer. The two phases 
or layers are formulated to be immiscible with one another. 
For the purposes of this invention, “immiscible” means that 
the solubility of one phase or layer is not more than 10 
gmilOO ml in an adjoining phase or layer and that the two 
adjoining phases or layers form an interface resembling a 
meniscus. 
Formulating the first phases or layer comprises combining 
a first solvent, a first polymer or microcapsule layer-forming 
compound soluble in the first phase, a co-solvent, an oil, and 
water. The first solvent will typically comprise about 
75-90% by volume of the first phase. The first polymer is 
selected to be one soluble in the first phase and typically will 
comprise about 1-5% by volume of the first phase. A small 
amount of a co-solvent is also added to the first phase, which 
co-solvent may also function as a co-surfactant. Oil com- 
prising about 1-10% by volume is also added to the formu- 
lation. The first phase will also contain about 1-5% water by 
volume. 
The method next calls for formulating a second phase 
immiscible with the first phase. The second phase comprises 
a second solvent, a second polymer soluble in the second 
phase, a surface active agent, and a salt. The relative, 
approximate volume percentages of these constituents is 
about 70-98% second solvent, 1-10% second polymer, 
1-4% surface active agent, and 1-3% salt. 
In order to ensure that the liquid-liquid interactions nec- 
essary to form the microcapsule will occur, certain of the 
constituents of each phase are selected relative to one 
another. Thus, the surface active agent in the second phase 
is selected such that it will have a hydrophilicilipophilic 
balance value greater than that of the first polymer constitu- 
5 
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ent of the first phase. Generally, the most useful surface 
active agents have been found to be those which are non- 
ionic and which have a hydrophilicilipophilic balance value 
of 10.0 or greater. Next, the second polymer constituent of 
the second phase is selected to have a hydrophilicilipophilic 
balance value lower than that of the surface active agent 
constituent of the same phase. While not an exhaustive list, 
certain hydrophilicilipophilic balance values of materials 
which may be used in the formulations of the invention are 
provided below. 
HYDROPHILICiLIPOPHILIC BALANCE [HLB) [McCutcheon 1979) 
Compound HLB 
Glycerol trioleate 
Cholesterol 
Triglyceride of coconut oil 
Sorbitan trioleate 
Sorbitan tristearate 
Glycerol monooleate 
Mono and di glycerides of fat burning fatty acids 
Glycerol Monostearate (GMS) 
Propoxylated ethylene diamine plus ethylene oxide 
Monoidiglyceride 
Glycerol mono coconut 
Monoidiglyceride 
Propylene glycol mono fatty acid ester 
Monoethoxyl lauryl ether 
Stearyl lactyl acid 
Hydrogenated cottonseed oil 
Mono and diglycerides with citric acid or lactylated ester 
or fatty acid 
Ethoxylated fatty amine (2 moles ETO) 
Diethylene glycol monostearate 
Sorbitan monopalmitate 
Diethylene glycol monostearate and oleate 
Ethoxylated (2) cetyl ether 
Glycerol Monoricinoleate 
Glycerol monolaurate 
Triglycerol mono stearate 
Polyethylene glycol (400 dioleate) 
Lanolin sterol 
Ethoxylated nonyl phenol (CO-420 & CO 850) 
Polyethylene glycol (400) distearate 
Sorbitan monolaurate 
Ethoxylated sorbitan fatty acid esters and alkyliaryl 
alcohol 
Anhydrous lanolin 
Polyethylene glycol monostearate 
Polyethylene glycol 400 
Ethoxylated (10) cetyl ether 
Ethoxylated glycerol monostearate (gms) 
Sorbitan monostearate 
Sorbitan monooleate with 20 moles ethylene oxide 
Ethoxylated (20) oleyl ether 
Ethoxylated (20) stearyl cetyl ether 
Ethoxylated castor oil 
Nonyl phenol polyethylene glycol ether 
Polyethylene glycol 600 mono laurate 
Sodium lauryl sulfate 
Propylene glycol monostearate 
Hydroxylated lanolin sodium oleyl sulfate 
Blends of GMS and sorbitan monooleate with 20 mols 
ethylene oxide 
0.8 
1.0 
1.4 
1.8 
2.1 
2.7 
2.8 
2.8-5.0 
(3.8 preferred) 
3-28 
3.2 
3.4 
3.5 
3.5 
3.6 
3.8 
3.8 
4.2-4.6 
4.5 
4.7 
4.7 
4.7 
5.3 
6.4 
6.8 
7.0 
7.2 
8.0 
8.0-16.0 
8.2 
8.6 
9.0 
10.0 
11.0 
11.2 
12.9 
13.1 
14.9 
15.0 
15.3 
15.8 
18.0 
18.1 
19.6 
40 
40 
42 
52 
The basic method next involves creating an interface 
between the first and second phases. The creation of the 
interface is achieved in such a way that minimal shear and 
mixing occurs between the phases. The two immiscible 
phases are brought together in such a mechanical manner 
that the fluid shear properties are controlled to low levels, 
below about 12 dynesicm’, and such that the adsorptive 
surface properties at the immiscible interfaces are not sig- 
nificantly altered. Although the exact mechanisms are not 
fully understood, the inventors believe that the maintenance 
5,827,531 
7 
of certain surface properties, such as the surface tension, 
Helmholtz charge distribution (electrical double layer), and 
partitioning of the surfactant molecules between the immis- 
cible phases must remain substantially intact so that lateral 
phase separation can occur in a manner which allows 
simultaneous formation of multiple liquid interfaces (oil/ 
water or waterioil) and which results in microcapsules 
having alternating spherical shells of hydrophilic and hydro- 
phobic liquid layers. This is believed to be the mechanism 
for the formation of multi-lamellar vesicles which are 
formed in a single step. Although this can best be demon- 
strated under microgravity conditions, wherein buoyant con- 
vection is absent and diffusion-driven convection 
predominates, this also can be accomplished in unit gravity 
conditions by balancing the density differences between the 
two liquid phases or by any other mechanical means which 
prevents excess fluid shear from significantly altering the 
normal adsorptive surface properties which are determined 
by the chemical composition of the formulas and the inter- 
facial phenomena among the solvents, polymers and surfac- 
tants. In a preferred embodiment, the creation of the inter- 
face will occur by sliding individually separated 
compartments containing the two phases into register with 
one another in a manner that substantially limits shear and 
provides gentle mixing. 
In the final step of the basic method, conditions are 
established in order to substantially limit all mixing between 
the interfaced liquid phases. In the most preferred 
environment, the two phases would be allowed to interact at 
their interface without agitation, stirring, shearing or like 
force. It is preferred to also limit even those quiescent forces 
such a gravity-controlled sedimenting, shifting, drift and the 
like. Thus, in certain preferred embodiments, only chiefly 
diffusion-driven convection is used to spontaneously form 
microcapsules, as the chemical formulations of the different 
phases assist in lowering the surface free energy across the 
interface. It is also at this time that formation of the 
polymeric outer coating is initiated. 
In one embodiment, the two liquids thus formulated are 
separated into distinct compartments or spaces which spaces 
are each connected to a central diffusion chamber into which 
each compartment can deliver its resident liquid loading. 
The compartments are initially closed to access into the 
central diffusion chamber so that the first and second liquids 
are kept apart from one another and not allowed to interact. 
While it is possible to use any number of devices to achieve 
this separation, a preferred device is a device like the 
Materials Dispersion Apparatus described in more detail 
below. The separation of the two liquids is maintained until 
both liquids and the device containing them can be placed in 
an environment in which convective mixing may be 
minimized, such as in a microgravity environment. 
The methods of the invention are slightly different 
depending upon whether the first solvent is selected to be 
organic or aqueous. Where an organic solvent is used to 
formulate the first phase, that organic solvent is selected 
from the group of organic solvents consisting of ethyl 
alcohol, methyl alcohol and isopropyl alcohol. Where an 
organic first solvent is used to formulate the first phase, the 
first polymer is selected to be one soluble in the organic 
solvent selected. Such a first polymer may be selected from 
the group of polymers consisting of glycerol monosterate, 
glycerol monooleate, glycerol monolaurate, glycerol 
dioleate, glycerol disterate, cholesterol, stigmasterol, 
phytosterol, campesterol, and lecithins such as phosphatidyl 
cholines (e.g., Centrolex-F'"). 
Where the first solvent is aqueous, a slightly different 
approach is taken. In those instances, the first polymer is 
8 
again requisitely soluble in the first aqueous phase and may 
be selected from the group of polymers consisting of poly- 
vinyl pyrrolidone, polyvinyl alcohols, gelatin, gum 
tragacanth, carrageenan, Karaya gum, Guar gum, gum 
5 arabic, alginates, carboxymethyl cellulose, hydroxypropyl 
cellulose, carboxypropyl cellulose, and lecithins. 
Regardless of the formulation with an aqueous or organic 
first solvent and polymer, the methods of the invention both 
use a co-solvent which may be selected from the group of 
co-solvents consisting of C,-C, alcohols, tetrahydrofuran, 
d i o x a n e ,  a c e t o n i t r i l e ,  d i m e t h y l f o r m a m i d e ,  
dimethylacetamide, and dimethyl sulfoxide. Similarly 
regardless of the organiciaqueous nature of the first solvent 
and polymer used, the methods of the invention add to the 
formulation of the first phase an oil. These oils may be 
selected from the group of oils consisting of unsaturated oils 
such as poppy seed oil, olive oil, peanut oil, sesame oil, 
cotton seed oil, soybean oil, safflower oil, corn oil, sunflower 
seed oil and canola oil or saturated oils such as mineral oil, 
long chain paraffinic oil, and liquid petrolatum. In a pre- 
20 ferred embodiment, poppy seed oil will be iodinated to form 
iodinated poppy seed oil (IPO) and incorporated into a 
microcapsule as a marker or tracer for tracking the presence 
of the microcapsule once injected via radiocontrast detection 
methods known well to those of skill in the art of radiog- 
Whether the method involves an organic or an aqueous 
first solvent, the second polymer, the surface active agent 
and the salt may each be selected from a particular group of 
such compounds. The second polymer may be selected from 
3o the group of polymers consisting of polyethyleneglycol 
1000-8000 daltons, dextran 1000-10000 daltons, 
polyvinylpyrrolidone, polyvinyl alcohols, gelatin, gum 
tragacanth, carrageenan, Karaya gum, Guar gum, gum 
arabic, alginates, carboxymethyl cellulose, hydroxypropyl 
cellulose, carboxypropyl cellulose, and lecithins. The sur- 
35 face active agent is selected from the group of surface active 
agents consisting of sorbitan monooleate treated with eth- 
ylene oxide, dextran, polyethylene glycol, C,,-C,, fatty 
acids, 2-amino-2-methyl-1-propyl aminomethyl propanol 
amphoteric salts and quaternary ammonium salts. The salt is 
40 selected from the group of salts consisting of NaC1, KC1, 
CaCl,, MgCl,, quaternary ammonium salts, cetyl trimethy- 
lammonium bromide and 4-methoxy-4(3-phosphatidyl 
choline)spiro(l,2-dioxetane-3-g,l-adamantane) disodium 
salt. 
In certain embodiments of the methods of the invention, 
pharmaceutical compositions will be incorporated into the 
microcapsule. Where such pharmaceuticals are thusly 
incorporated, they may be introduced initially as a solute or 
as particulates suspended in one or the other of the liquids 
SO used to formulate the layers of the microcapsules. In certain 
embodiments, the pharmaceutical is introduced in one of the 
phases or layers used to produce the microcapsule at a 
concentration sufficient to allow nascent crystal formation 
within said microcapsule. Crystal formation may occur at or 
ss near the time of formation of the microcapsule containing 
the dissolved pharmaceutical material. The aqueous solvent 
system used to dissolve an aqueous-soluble pharmaceutical 
is selected to permit water molecules to migrate away from 
the drug-containing layer into the alcoholic mixture. The 
60 process of crystal formation is likely to be promoted in this 
manner after formation of the microcapsule. In fact, it is 
possible to enhance the crystallization process after the 
microcapsule is formed by controlled transport of the sol- 
vent phase or layer in which the pharmaceutical to be 
65 crystallized is a solute. It certain embodiments, the crystal 
thus formed may take up most of the internal capacity of the 
microcapsule. 
25 raphy. 
45 
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Multi-layered microcapsules, with both hydrophobic and 
hydrophilic drug compartments, as produced by the methods 
of the invention enable diffusion of complimentary drugs 
from the same microcapsule, e.g. antibiotics and immuno- 
stimulants to treat resistant infections or multiple fibrinolytic 
drugs to dissolve emboli. Co-encapsulation of radio-contrast 
medium as provided herein enables oncologists to monitor 
the delivery of anti-tumor microcapsules to target tumors 
using computerized tomography and radiography that track 
the distribution of microcapsules after release from the 
intra-arterial catheter. Such microcapsules will have impor- 
tant applications in chemotherapy of certain liver, kidney, 
brain and other tumors. 
The diameters of microcapsules possible to attain using 
the methods of the invention are also of particular usefulness 
in medical applications. Thus, whereas prior art methods 
have been able to routinely produce microspheres over 1-10 
micron average sizes, the present invention’s methods pro- 
vide similarly-sized microcapsules of 1-20 micron diam- 
eters for intravenous administration. Also provided are 
50-300 micron sized microcapsules particularly useful in 
interarterial chemoembolization of tumors, and microcap- 
sules in the range of 300 micron and greater diameters useful 
in interperitoneal administered drugs. 
The pharmaceutical composition encapsulated in the 
microcapsule may be one soluble in aqueous solutions or 
may be one soluble in organic solutions. This, of course, 
governs the selection of the phase or layer in which the 
pharmaceutical composition is formulated. The microcap- 
sules of the invention and methods for producing them are 
of particular utility when formulating organic-soluble drugs 
as these type of drugs are otherwise very difficult to admin- 
ister. The pharmaceuticals may be those selected from the 
group of such widely diversified pharmaceutical composi- 
tions as that consisting of cytoxins, proteases, cytokines, 
anti-nauseants, steroids, anti-fungal agents, fibrinolytic 
enzymes, and antibiotics. The inventors have successfully 
encapsulated representatives of these classes of pharmaceu- 
ticals using the methods of the invention. It is also possible 
to incorporate a pharmaceutical composition which is not 
initially dissolved in one or another of the phases or layers, 
but rather which drug is in suspension. As noted above, 
depending upon its solubility and upon where the pharma- 
ceutical chemist wishes to locate the drug, it is possible to 
formulate a drug in any of the phases or layers, by dissolving 
or suspending the drug as needed. 
The methods of the invention surprisingly demonstrated 
the ability to package very high concentrations of drugs in 
the layers formed. It is possible, using the methods of the 
invention, to formulate a pharmaceutical at a concentration 
sufficient to allow nascent crystal formation within the 
microcapsule once it is formed. These microcapsules, due in 
one regard to their being constructed with outer polymeric 
coatings, are also particularly flexible yet rugged (able to 
withstand shear forces greater than 10 dynesicm’). As will 
be related specifically below, microgravity experiments, on 
sounding rockets (1989-92) and Shuttle missions STS-52 
(1992) and STS-56 (1993) using an automated Materials 
Dispersion Apparatus, produced multi-lamellar microcap- 
sules containing both Cis-platinum (anti-tumor drug) and 
iodinated poppy seed oil (a non-radioactive, radiocontrast 
medium), surrounded by a polymeric skin. Microcapsules 
formed with amoxicillin (antibiotic) or urokinase (a clot 
dissolving enzyme), co-encapsulated with IPO, were still 
intact after two years after return to l x g  environments. In 
many instances, microcapsules were formed with the Cis- 
Platinum or amoxicillin so concentrated that crystals of the 
drugs formed inside. 
10 
Surprisingly, the methods of the invention have demon- 
strated a unique ability to encapsulate such saturated drug 
solutions, and since the overall partitioning characteristics 
between immiscible layers facilitates solvent transport out of 
5 the aqueous layer, it is possible to concentrate the drug to the 
point that formation of drug crystals occurs within the 
microcapsules. This ability of the microcapsules and meth- 
ods of the invention provides the maximum drug payload 
per microcapsule and the best drug release kinetics for 
prolonged treatment at maximum drug diffusion rates. 
Microcapsules containing a large volume component of 
crystalline drug provide the most concentrated drug possible 
when it is released at the target site. Until the crystals are 
completely dissolved, the drug release rate is independent of 
1s time (zero order release kinetics). When the crystals have 
dissolved, the drug release rates revert to first order kinetics 
(exponential with time). The encapsulated crystals of the 
invention are in the range of 1-50 microns in diameter. Since 
these crystals are precipitated in situ, they are quite different 
2o from the other commercially-available crystalline drug 
delivery systems (e.g., MicrocrystalTM) which use phospho- 
lipids to encapsulate tiny particles or crystals of drugs with 
an average diameter of only 0.3-1.0 micron [Parikl and 
Stern 19941. 
It is also possible to additionally treat the microcapsules 
thus formed with additional steps. In some instances, the 
methods of the invention, regardless of whether they ini- 
tially use an organic or an aqueous first solvent, formulate a 
third phase comprising an oil or C,,-C,, paraffin and, 
30 contact the formed microcapsule with the third phase. In 
other instances, the methods of the invention form a two- 
layered microcapsule, then formulate a third phase compris- 
ing an aqueous solution and, contact the formed microcap- 
sule with the third phase. The basic method and alternatives 
2s 
35 are summarized below. 
Group 1 Group 2 
Solution 1 Solvent 1 is a hydrocarbon Solvent 1 is aqueous 
soluble, selected to form the soluble, but can be extended 
outer coating (typically of into organic phase (includes 
lower HLB values) phospholipids) Ex. Centrolex 
F TM 
Co-solvents alcohols, hydro- Co-solvents same, but often 
carbons (act as co-surfactants) less % 
Oils saturated or unsaturated Oils same 
oils 
Drug dissolved (or suspended Drug dissolved (or particulate) 
particulate) 
Solution 2 Solvent 2 aqueous Solvent 2 same 
Polymers water soluble (PEG, Polymers same 
Surfactants (typically higher 
HLB value) less % 
Salts ionic, quaternary 
ammonium salts % 
Drugs aqueous soluble 
Polymers hydrocarbon-soluble Polymers same 
Drugs can be included 
Alternative aqueous solution 
coating-adjuvants immuno- coating same 
60 globulins polymer same 
polymers - aqueous soluble 
surfactants - 
40 Polymers are hydrocarbon Polymers (skin) are water 
4s 
so Dextran) 
Surfactants same but often 
Salts same, but often different 
Drugs aqueous soluble 
55 Solution 3 Oils hydrocarbons Oils same 
Drugs can be included 
Alternative aqueous solution 
.. OR .. .. OR .. 
surfactants same 
Traditional emulsion methods form a O/W/O (oiliwateri 
65 oil) or WIOIW (waterioiliwater) liquid system which is 
designed to retain the internal phase(s) within the external 
solvent unless the emulsion is broken, whereupon the liquid 
5,827,531 
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phases separate. In the methods of the invention, the use of 
surfactants and co-surfactants permits formation of an emul- 
sion of large spheroids (not small microspheroids) of one 
phase dispersed in the other phase configured in a sphere. 
The sphere is also surrounded by another immiscible liquid 
layer (opposite phase to that of the innermost liquid sphere) 
and then (often) this multi-layered sphere is contained in 
another opposite-phase liquid layer and finally the entire 
multi-layered sphere is contained in an outer skin. The 
results of the process of the invention are not to form a 
traditional OIWIO or WIOIW emulsion (which is a fine 
dispersion of one phase in another), but rather to form 
multi-lamellar, alternating immiscible-layer microcapsules 
with unique immunologic, pertinacious or other surface 
characteristics which makes them selectively adhere to 
certain target tissues (cells) or renders the microcapsules 
attractive to certain phagocytic cells (when the cells are the 
5 actual target for the therapeutic drug). Where the adjuvant is 
a hydrocolloid, it may be selected from the group of such 
hydrocolloids consisting of collagen, isoelectric gelatin, 
agar, gum arabic, gum tragacanth, alginates, cellulose 
derivatives and carrageenans. The third phase may also 
further comprise a surface active agent. 
The third aqueous phase can also contain a chemical 
activator which acts upon the inactive form of the pharma- 
ceutical agent (drug) as it diffuses out of the inner layers of 
contained within a thin, semi-permeable outer skin. In the the microcapsule. The function of the activator is to chemi- 
microcapsules of the invention, the immiscible phases are 15 cally convert the inactive drug to its active form just before 
distinct and separated according to the surface tension it is released from the microcapsule. This is illustrated when 
characteristics of the liquids at each interface, hence there is the pharmaceutical is a pro-enzyme and where the activator 
no true emulsion maintained by the surfactant which could is another proteolytic enzyme which cleaves the pro-enzyme 
be broken. at active site to render the molecule biologically active. This 
Thus, in certain embodiments of the methods and corn- 2o embodiment can be used to deliver very labile drugs which 
positions of the invention, the multi-layered microcapsule have very limited shelf-lives or short biological half-lives 
will be produced which comprises at least three alternating whereupon the activator (third phase) can be added shortly 
layers or phases. Thus, if the first layer is an aqueous layer prior to intravascular administration such that the inactive 
or core, the next layer may be an organic layer. This organic drug becomes activated after the microcapsules have 
layer may then be covered Over by a second aqueous layer 25 reached the target site. This can maximize the therapeutic 
which forms on its outer surface a polymeric skin. effectiveness of the short-lived drug at the target site of 
Conversely, the liquid at the core of the microcapsule may action. 
be an organic liquid layered over by an aqueous layer One or more of the phases of the microcapsule of the 
followed by another organic layer which forms a polymeric invention may further comprise fluorescent molecules 
skin over the surface of the microcapsule. Certainly, exten- 30 selected from the group of fluorescent molecules consisting 
sion of these basic formulations may be envisioned where of fluoresceins, cyanins, naturally fluorescent molecules, 
four or more layers are possible or where multiple skins or and rhodamines. This is particularly useful where radiocon- 
coatings are utilized. trast media are not desirable or where an additional tracking 
Whether used in conjunction with a two-layer microcap- method is useful or where it is of value to monitor the 
sule or with microcapsules with more than two layers, the 35 presence or absence of a layer in the microcapsule, fluores- 
coatings of the present invention are of substantial utility, cent molecules may be incorporated into the microcapsule of 
particularly when the methods are carried out at earth- the invention. Thus, for instance, as described more fully 
normal gravity. The coatings can be either substantially of a below, it may be useful to incorporate a hydrophilic flw- 
hydrophobic nature or of a hydrophilic nature as described rescent molecule in the aqueous liquid in order to determine 
below and are derived from addition of certain polymers in 40 the relative location and number of aqueous liquid layers in 
the initial formulations of the liquids used to make the a certain production batch of microcapsules produced by the 
microcapsules. Where hydrophobic coatings are used in methods of the invention. 
conjunction with drug-delivery systems, the coatings are Critical to the success of the methods of the invention is 
selected for their complementary permeability to the drug to the substantial limitation of mixing between said phases to 
be delivered. The polymers are also selected for their 45 diffusion-driven convection. One manner in which to so 
flexible characteristics after formation and curing which is limit other types of mixing is to carry out the methods under 
of particular utility during intravascular transport and allows microgravity. Microgravity is defined as a gravity force of 
higher packing densities for forming emboli such as in less than I ~ l O - ~ x g .  Such gravitational environments may be 
chemoembolization therapy. Thus, for example where a achieved in a variety of ways, at least some of which are 
water-soluble drug is to be delivered, the drug is contained 50 detailed herein. For instance, microgravity may be achieved 
in an inner aqueous layer over which is placed a coating in certain trajectories of sounding rockets. Even longer 
permeable to the dissolved drug. Preferably, the coating periods of microgravity may be obtained with temporary 
material should be impermeable to solvents or oils. The orbiters such as the space shuttle. Relatively indefinite 
coatings which have been observed to be deposited on the periods of microgravity may be obtained in permanent or 
surfaces of the microcapsules of the invention are about 5s semipermanent orbital space craft such as the orbital space 
0.01-2.0 microns thick where the coating is a hydrophobic station and other geosynchronous orbital satellites. The 
coating, and about 0.1-5.0 microns thick where hydrophilic exposure of the first and second liquids to microgravity has 
coatings are deposited. been found to be effective in forming the microcapsules of 
The additional steps and third formulated phases may also the invention where the exposure is at least 6.5 minutes in 
be used advantageously to provide the microcapsule with 60 duration. Certainly, as described more fully below, greater 
specific characteristics. Thus, the third phase may further exposure periods have also been proven successful. The 
comprise a pharmaceutical composition which is added to inventors anticipate that periods of exposure as short as 1.0 
the formed surface of the microcapsule. The third phase may minute will also produce adequate numbers of microcap- 
also be used to add a pharmaceutical composition such as an sules. 
adjuvant. The adjuvant may further comprise an 65 In preferred embodiments, however, the methods of the 
immunoglobulin, other protein, hydrocolloid or polysaccha- invention will not use microgravity in order to limit mixing 
ride. This is of particular utility in designing microcapsules between the phases. Of course, such limitations of mixing 
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can be promoted by carrying out the methods below ambient are used to form unique multi-lamellar, microcapsules, hav- 
temperature. Limitation of interactions between the phases ing alternating hydrophilic and hydrophobic liquid layers 
is best promoted by substantially balancing the specific surrounded by a flexible, semi-permeable, polymeric outer 
gravity between said phases as is described below. The “skin”. The outer skin which can be either hydrophilic or 
formulations and methods necessary to achieve earth- 5 hydrophobic, is designed to allow controlled drug diffusion 
normal microcapsule formation are described in greater out of the microcapsule. 
detail herein. In either case, or in combinations of these Unlike any natural phospholipid or other component of 
techniques, mixing between the two phases may be chiefly cell membranes, the outer skin of the microcapsules of the 
the result of diffusion-driven convection. invention avoids recognition and phagocytosis by immune 
The inventors have found that there is a greater size cells, thereby increasing the amount of drug delivered to the 
distribution which results from microencapsulation at earth- tissues. The multi-layered microcapsules of the invention 
normal gravity. At least a partial reason for this wider size can entrap multiple drugs in different solvent compartments 
distribution is apparently the inability under earth-normal and saturated solutions of drugs which may then form 
gravity to avoid certain sedimentation phenomena alone and crystals inside the microcapsule. Radiocontrast medium can 
sedimentation effects combined with weight-related contact be co-encapsulated with drugs in the same microcapsule. A 
of sedimented microcapsules. These facts require some magnetic resonance contrast agent can also be encapsulated 
additional manipulation under earth-normal environments such as various metallo-organic compounds including aque- 
not required in the Oxg environments-namely, sieving of ous soluble ferrous gluconate, Gadolinium diethylene tri- 
the resulting microcapsules in order to generate more uni- amine pentaacetic acid and hydrocarbon-soluble, iron pen- 
form fractions. Therefore, at earth normal gravity, the utility tacarbonyl. 
of the outer coating of the microcapsules of the present 20 The microcaps&s of the invention have been found to 
invention become even more important. Enhancing the provide a surprisingly uniform distribution of diameters 
ruggedness of the earth-normal microcapsules by curing and (FIG. 3A and B). This uniformity is particularly important in 
other steps as related herein may also be used. its medical applications. The microcapsules thus produced 
Apreferred method of making a multi-layered microcap- can be used to deliver several drugs which can be released 
sule comprises: formulating a first phase comprising an 2s sequentially to the target tissues. The deformable, liquid- 
organic solvent selected from the group of organic solvents filled microcapsules also have advantages over solid matrix 
consisting of ethyl alcohol, methyl alcohol and isopropyl microspheres in achieving maximum packing density in 
alcohol, a first polymer soluble in the first phase selected blood vessels, thereby decreasing blood flow to target tis- 
from the group of polymers consisting of glycerol sues. This enhances the therapeutic effect of combined drug 
monosterate, glycerol monooleate, glycerol monolaurate, 30 delivery and reducing the blood supply to vascular ~ U I K N ~  
gl  y c e r o 1 dio le a t e ,  g l  y ce r o 1 dis  t e r a t e ,  c ho le s t e r o 1, (chemoembolization). 
stigmasterol, phytosterol, campesterol, lecithins such as The methods of the invention result in more spherical, 
phosphatidyl cholines (e.g., Centrolex-FTM), a co-solvent uniform size distributions of microcapsules. When compar- 
selected from the group of co-solvents consisting of C,-C, ing certain prior art equipment and methods for forming 
alcohols ,  te t rahydrofuran,  dioxane,  acetoni t r i le ,  35 microcapsules (Microfluidics, Inc., see FIGS. 2 4  B and3-4, 
dimethylformami&, dimethylacetamide, and dimethyl B), the inventors found that even the preferred formulations 
sulfoxide, an oil selected from the group of oils consisting of the invention were incapable of providing such unifor- 
of poppy seed oil, olive oil, peanut oil, sesame oil, cotton mity. In certain instances, hardly any microcapsules formed 
seed oil, soybean oil, safflower oil, corn oil, sunflower seed at all where mixing and vortexing were used to distribute 
oil, canola oil (unsaturated oils), or mineral oil, long chain 40 one phase into the next (FIG. 2 4 .  In others, poorly formed 
paraffinic oil, and liquid petrolatum (saturated oils), and and non-spherical microcapsules resulted (FIG. 2B). In 
phase, the second phase comprising water, a second polymer of the invention were successfully used to generate uniform, 
soluble in the second phase selected from the group of spherical microcapsules both under unit gravity (FIG. 3 4  
daltons, dextran 1000-10000 daltons, polyvinylpyrrolidone, mity enables superior drug delivery. Enhanced uniformity 
water; formulating a second phase immiscible with the first contrast to the failures of the prior art methods, the methods 
polymers consisting of polyethyleneglycol 1000-8000 45 and under microgravity conditions (FIG. 3B). Such unifor- 
polyvinyl alcohols, gelatin, gum tragacanth, carrageenan, also enables better dose distribution calculations for estab- 
Karaya gum, Guar gum, gum arabic, alginates, carboxym- lishing the therapeutic dose in the treatment of specific 
ethyl cellulose, hydroxypropyl cellulose, carboxypropyl diseases, especially treatment of certain types of tumors. 
cellulose, lecithins, a surface active agent selected from the 50 Importantly, the methods of the invention allow the forma- 
group consisting of sorbitan monooleate treated with ethyl- tion of larger-sized, multi-lamellar microcapsules (1-350 
ene oxide, dextran, polyethylene glycol, C,,-C,, fatty acids, micron) than heretofore possible. Such a capability allows 
quaternary ammonium salts, and a salt selected from the multilamellar microcapsules to be made specifically for 
group of salts consisting of NaC1, KC1, CaCl,, MgC1, , inhalation and deposition in the lungs. This uniformity 
quaternary ammonium salts, cetyl trimethylammonium 5s allows facile sieving or filtering of the microcapsule prod- 
bromide, 2-amino-2-methyl-l-propyl aminomethyl ucts in order to obtain highly uniform diameter fractions. 
propanol, and 4-methoxy-4(3-phosphatidyl choline)spiro(l, Most liposomes have a very small hydrophobic compart- 
2-dioxetane-3-g,l-adamantane) disodium salt; the surface ment and therefore can only carry small amounts of hydro- 
active agent having a hydrophilicilipophilic balance value phobic drugs. Contrastingly, the microcapsules of the inven- 
greater than that of the first polymer; the second polymer 60 tion have a relatively large hydrophobic liquid compartment 
having a hydrophilicilipophilic balance value lower than that which enables delivery of more hydrophobic drug per 
of the surface active agent; creating an interface between the microcapsule. Moreover, the microcapsules of the invention 
first and second phases in a manner that substantially limits have relatively large hydrophilic and hydrophobic compart- 
fluid shear; and, substantially maintaining adsorptive surface ments which permits tandem delivery of both water soluble 
characteristics of said interface. 65 and non-water soluble drugs in the same microcapsule. 
Microcapsule products produced by any of the methods of As previously noted, the microcapsules of the invention 
the invention are also claimed. The methods of the invention may contain polysaccharides. Inclusion of such polysaccha- 
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rides is one of several aspects of the methods of the 
invention that enhance the formation of the microcapsules. 
The inclusion of injectable polysaccharides in the formula- 
tions of the invention (similar to those polysaccharides 
found in Ringer’s solutions) contributes to the driving forces 
that control phase separation and phase partitioning of the 
entrapped drugs. The polysaccharides also provide increased 
shelf-life and stability of the parenteral suspensions. Use of 
the osmotically neutral salt solutions in the aqueous phase 
enhances micelle formation, lateral phase separation, and 
increases the dispersion of microcapsules and their stability 
as they are formed. 
The methods of the invention in a preferred embodiment 
utilize a non-phospholipid outer coating. The microcapsules 
formed by this method are contained in a thin, semi- 
permeable, outer membrane comprised of hydrophobic (e.g. 
mono- or polyglycerides or waxy-polymers) or hydrophilic 
polymers (e.g., PVA or PVP), depending on the desired 
diffusion release rate of the encapsulated drug. Thus, the 
coating has the advantage of allowing design of the appro- 
priate drug diffusion and release characteristics while avoid- 
ing certain of the disadvantages of conventional liposomes 
(and lipid bilayers). In particular, the coating produced by 
the methods of the invention around the outer surface of the 
microcapsule avoids being readily detected and largely 
eliminated by the reticuloendothelial system (RES). The 
outer skin protects the microcapsules against shear forces 
encountered during manufacturing processes and during 
transport within the vascular system enroute to the target 
tissues. The hydrophobic outer membrane also can be 
designed to retard oxygen transport, thereby reducing oxi- 
dative degradation of the entrapped drug and improving the 
shelf-life of the parenteral suspensions. The flexible/ 
deformable outer skin on the microcapsules of the invention 
results in increased packing densities within vascular beds. 
This results in microcapsules superior to solid microspheres 
(e.g. gelatin, albumin or starch) commonly used for 
chemoembolization therapy against tumors. The formula- 
tions used to produce the microcapsules of the invention are 
summarized below. 
Formulas for Primary, Secondary and Tertiary Solutions 
for Microencapsulation 
Primary Solution Tertiary Solution 
(also can contain (also can contain 
drug) Secondary Solution dissolved drug) 
Group 1 First Solvent 
175-90%) 
ethyl alcohol 
methyl alcohol 
isopropyl alcohol 
Organic Co-solvent 
0-20% 
Second Solvent 
water (70-98%) 
Polymers 
(1-10%) 
polyethylene glycol 
PEG - 1000-8000 
ioolvsaccharides’l 
C,-C, alcohols 
tetrahydrofuran 
dioxane 
acetonitrile 
dimethylformamide 
dimethyl sulfoxide 
(DMSO) 
(THF) 
(DMF) 
Dextran 4000- 
20000 
(range 10000- 
others 
polyvinyl- 
pyrrolidone 
polyvinyl alcohols 
Surfactants (ionic 
100000)) 
- 
Oils (up to 100%) 
IPO 
heavy mineral oil 
olive oil 
same as in primary 
soh .  
paraffins (c2043S) 
Alternative 
Aqueous solutions 
containing - 
immunoglobulins 
albumin 
gelatin 
hydrocolloids 
plant sterols 
phospholipids 
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-continued 
Formulas for Primary, Secondary and Tertiary Solutions 
for Microencapsulation 
5 Primary Solution Tertiary Solution 
(also can contain (also can contain 
drug) Secondary Solution dissolved drug) 
Polymers 
(1-5%) (mono- 
glycerated) 
glycerol mono- 
stearate 
glycerol monooleate 
glycerol mono- 
laurate 
(polyglycerides) 
glycerol dioleate 
glycerol distearate 
10 
1s 
20 (sterols) 
cholesterol 
plant sterols - 
stigmasterol 
phytosterol 
2s  campesterol 
(phospholipids) 
lecithins 
e.g., phosphatydl 
(Centrolex-F TM) 
Water (1-5%) water 
Oils (unsaturated 
or saturated) 
30 choline 
3s (1-10%) 
iodinated poppy 
seed oil (IPO) 
mineral oil 
cotton seed oil 
olive oil 
safflower oil 
canola oil 
peanut oil 
sesame oil 
corn oil 
Dissolved Drugs 
(1% to saturation) 
Group 2 Aqueous First 
Solvent water 
(70-90%) 
40 
4s 
so Co-solvents 
(0-20%) 
C3-C, alcohols 
tetrahydrofuran 
(THF) 
5s dioxane 
acetonitrile 
dimethylformamide 
dimethyl sulfoxide 
(DMSO) 
philic (water 
soluble) 
(DMF) 
60 Polymers hydro- 
and non-ionic) polysaccharides 
(14%) starches 
sorbitan cyclodextrins 
monooleate plus Polymers 
ethylene oxides Surfactants (1-4%) 
Dextran (ionic and non- 
PEG ionic) 
C,,4,0 fatty acid long chain 
quaternary NH, salt amphoteric salts 
Additional Polymers celluloses 
(1-10%) Additional Polymers 
(hydrocolloids) Same as secondary 
gelatin solution 
gum tragacanth Dissolved Drugs 
carrageenans (1% to saturation) 
karaya gum soluble therapeutic 
guar gum 
alginates 
(celluloses) 
celluloses (CMC, 
WEC, HPC) 
Salts (1-3%) 
NaCl 
KC1, CaCl,, 
quaternary NH, 
salts, cetyl 
trimethylammonium 
bromide, 2M2A- 
AMP, PPD 
Dissolved Drugs 
(1% to saturation) 
therapeutic of 
choice 
Same as Group 1 
Co-Solvents Same as Group 1 
Same as primary Alternatives 
solution Aqueous solutions 
Polymers (1-10%) 
Same as Group 1 Surfactants 
Surfactants (1-20%) Same as Secondary 
(ionic and non- Solution 
ionic) Same as Dissolved Drugs 
Group 1 1% to saturation 
Additional Polymers 
1-10% 
Salts (1-3%) 
Same as Group 1 
Dissolved Drugs 
1% to saturation 
Oils (up to 100%) 
Same as Group 1 
polyvinyl- 
pyrrolidone (PVP) 
65 polyvinyl alcohols 
(PVA) 
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-continued 
Formulas for Primary, Secondary and Tertiary Solutions 
for Microencapsulation 
Primary Solution Tertiary Solution 
(also can contain (also can contain 
drug) Secondary Solution dissolved drug) 
hvdrocolloids 
gelatin 
gum tragacanth 
carrageenans 
karaya gum 
guar gum 
alginates 
celluloses CMC: 
CPC 
phospholipids 
lecithins 
phosphatydl choline 
Centrolex F 
polysaccharides 
corn starch 
cyclodextrins 
Oils (unsaturated or 
saturated) 1-10% 
iodinated poppy 
seed oil (IPO) 
mineral oil 
cotton seed oil 
olive oil 
safflower oil 
canola oil 
peanut oil 
sesame oil 
corn oil 
Dissolved Drugs 
1% to saturation 
The formulations of the invention, in preferred 
embodiments, are less toxic than conventional liposomes 
and other microcapsules by avoiding use of certain phos- 
pholipids and long chain amines (eg. Stearylamine) con- 
tained in conventional microspheres which can produce 
toxic side effects. 
Where the microcapsules of the invention comprise a 
pharmaceutical composition, certain medically related 
advantages may be obtained. Thus, due to the uniformity and 
ease with which the methods of the invention allow forma- 
tion of multilamellar microcapsules, co-encapsulation of 
multiple drugs is made possible. Thus, for instance, as will 
be described more fully below, co-encapsulation of drugs 
and radiocontrast medium in the same microcapsules is 
made possible by the methods of the invention. Such 
co-encapsulation allows radiological monitoring of the tis- 
sue distribution during intravascular delivery. Additionally, 
incorporation of fluorescent-labels for entrapped drugs 
enables accurate measure of the drug compartment volumes 
(using fluorescent imaging techniques) and convenient 
determinations of the drug loading efficiencies, particle size 
distributions and measurement of shelf-life stability of the 
final parenteral suspensions. In some applications made 
possible by the methods and compositions of the invention, 
the organic phase can include a tracer compound or radio- 
contrast medium to provide the additional advantage of 
real-time imaging of the microcapsules with computerized 
tomography (CT) scanning as they are released from the 
catheter enroute to the target tissue. Other examples include 
aqueous soluble metallo-organic compounds used for diag- 
nostic imaging such as ferrous gluconate or Gadolinium 
diethylene triamine pentaacetic acid (Gd-DTPA) used for 
nuclear magnetic resonance imaging and hydrocarbon 
soluble agents such as iron pentacarbonyl which also may be 
used for NMR imaging. 
Production of multi-layered microcapsules via the meth- 
ods of the invention which possess alternating hydrophobic 
5 and hydrophilic drug compartments allows for design of 
multiple-therapy microcapsules. Spontaneous formation of 
microcapsules with one or more large hydrophobic solvent 
compartments increases the potential application for deliv- 
ery of more aqueous-insoluble drug at target sites with 
adequate vascular networks. By using the microcapsules 
made possible by the methods of the invention, sequential 
diffusion of two or more drugs out of the same microcapsule 
may be achieved at the target tissues. The incorporation of 
aqueous-soluble cyclodextrin which can act as an internal 
hydrophobic drug carrier is also made practical using the 
single step methods and formulations provided in this inven- 
tion. This extends the capability of the invention in deliv- 
ering otherwise aqueous-insoluble drugs. 
For instance, the use of multiple drugs within the same 
microcapsule provides microcapsules specifically designed 
20 for chemoembolization treatments. Multiple-drug microcap- 
sules also may be used to deliver first a chemotherapeutic 
drug which kills tumor cells, and then an immuno-adjuvant 
(tumor necrosis factor) or immunological stimulant (e.g. 
interferon-g) that would enhance the patient’s immune 
2s response to the tumor. Multiple-drug microcapsules can also 
be used to deliver combinations of chemotherapeutic drugs 
to tumors that are located in privileged sites, such as brain 
tumors. For example, and as described more fully in the 
examples to follow, simultaneous delivery of different types 
30 of drugs in the same microcapsule is made possible with the 
methods and compositions of the invention, e.g. diaziquone 
and cis-platinum to brain tumors via the carotid artery 
[Kimier et al. 19931. Multi-layered microcapsules may also 
be used to treat deep infections that are resistant to systemic 
35 antibiotics. In these applications, one or more antibiotics 
may be sequentially delivered to the site of the infection. 
Multi-layered microcapsules can be designed to protect 
active forms of urokinase and other thrombolytic enzymes 
until they are delivered and entrapped at the local site of a 
40 blood clot, where therapeutic doses of the enzyme may then 
diffuse out to dissolve the unwanted embolism. The multi- 
lamellar microcapsules can also be used to deliver immu- 
nostimulants; cytokines such as Interferons, Interleukins, 
and growth factors; antinauseants such as metoclopramide 
45 and tetrahydrocannabinol; multiple fibrinolytic enzymes 
such as urokinase (uPA), tissue plasminogen activator (tPA) 
and streptokinase; steroids such as hydrocortisone, 
dexamethasone, etc.; anti-fungals such as nystatin and 
griseofulvin, anti-virals such as amatidine, iododeoxuridine, 
50 riboviran; and multiple antibiotics such as amoxicillin, 
ampicillin, etc. 
In one embodiment, as related to the space-based research 
that lead to the earth-normal embodiments of the invention, 
exposure to microgravity for at least 1.0 minutes in duration 
ss is accomplished. If the microcapsules of the invention are to 
be used in l x g  environments, as is generally anticipated, an 
additional step comprising recovering the multi-layer micro- 
capsules will be necessarily accomplished at earth normal 
gravity. Generally, this step will be accomplished by reentry 
60 and recovery of the orbital device by which exposure to Oxg 
was accomplished. While it is preferred to accomplish the 
recovery without exposure of the formed microcapsules to 
physical extremes (pressure, temperature, shearing, mixing, 
etc.), recovery of the microcapsules of the invention have 
65 been accomplished via a transition from microgravity to 
earth normal gravity at accelerations of at least 15xg without 
substantial loss of integrity. 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1.  Conceptual schematic showing formation of a 
multi-lamellar microcapsule with an aqueous drugioil dis- 
persion at its center, a hydrocarbonioil drug #2 and/or 
radiocontrast medium (e.g. IPO) as a next layer, aqueous 
layeridrug (cis-platinum) as a next layer, and a polymer 
outer skin. 
FIG. 2A and 2B. Photomicrographs of prior art method 
(vigorous mixing) to make microcapsules. FIG. 2A shows a 
typical result which fails to form microcapsules. FIG. 2B 
depicts certain best efforts to form microcapsules using prior 
art method. 
FIG. 3A and 3B. Photomicrographs depicting the distri- 
bution of sizes of microcapsules resulting from the methods 
of the invention are applied to form microcapsules. FIG. 3A 
shows the typical result when the methods used under unit 
gravity. 
FIG. 3B shows similar results when microcapsules are 
formed using the microgravity methods of the invention. 
FIG. 4. Photomicrograph at enhanced magnification over 
that of FIG. 3A and B showing details of certain microcap- 
sules of the invention. 
FIG. 5. Photomicrographs of a microcapsule of the inven- 
tion which was made with a fluorescent dye. A shows a 
single microcapsule without using fluorescence microscopy. 
B shows the same microcapsule as photographed using 
fluorescence microscopy. 
FIG. 6Aand 6B. Microcapsules with crystalline structures 
in their internal layers or shells. FIG. 6A shows a micro- 
capsule with a single cubic crystal of Cis-Platinum trapped 
within. FIG. 6B shows a microcapsule with numerous 
crystals of Cis-Platinum formed within. 
FIG. 7. Microcapsules which have been treated to contain 
a radio-contrast oil (iodinated poppy seed oil) and crystals of 
Cis-Platinum. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
A series of more than 38 separate experiments on four 
space flights has led to the development of this invention. 
These experiments along with their ground-based counter- 
parts are described below for the purpose of pointing out the 
invention specifically and providing details useful in carry- 
ing out the invention. These specific examples, however, do 
not limit the scope of the claimed invention. 
Referring first to the figures, FIG. 1 is a conceptual 
schematic showing formation of a multi-lamellar microcap- 
sule 10 with an aqueous drugioil dispersion 12 at its center 
14, a hydrocarbonioil drug#2 and/or radiocontrast medium 
(e.g. IPO) 16 as a next layer 18, an aqueous layeridrug 
(cis-platinum) 20 as a next layer 22, and a polymer outer 
skin 24. A first hydrocarbon phase 26 and a second aqueous 
phase 28, initially separated, are allowed to form an inter- 
face 21  with minimal mixing and low shear. If only 
diffusion-driven convection is allowed to occur at interface 
21  thereafter, microcapsules of the invention form represen- 
tative of that depicted 10. 
FIG. 2 is a pair of photomicrographs of the resulting 
mixture when a prior art method (utilizing vigorous mixing) 
is used with the preferred formulations of the invention to 
attempt to make microcapsules at earth normal gravity. FIG. 
2A shows a typical result which fails to form microcapsules 
of any kind. FIG. 2B depicts certain best efforts to form 
microcapsules using this method. In FIG. 2B, in can be seen 
that certain poorly formed microcapsules 30 have formed. 
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Typically, these microcapsules will demonstrate consider- 
able lack of sphericity 32, coalescence 34, and non- 
uniformity 36. 
In FIG. 3, a pair of photomicrographs of the resulting 
mixture of when the methods of the invention are applied to 
form microcapsules. FIG. 3A shows the typical result when 
the methods of the invention are used to form microcapsules 
under unit gravity, at temperatures below ambient. Numer- 
ous microcapsules wherein the first phase is an organic 
phase formed, including certain ones of considerable diam- 
eter 40 as well as those of fairly small diameter 42. FIG. 3B 
shows similar results when microcapsules are formed using 
the microgravity methods of the invention using a first 
aqueous phase. Again, numerous microcapsules, including 
certain ones of considerable diameter 44 as well as those of 
fairly small diameter 46 form. It is clear from such 
photomicrographs, that uniformity and sphericity is a com- 
mon characteristic of the microcapsules of the invention, 
regardless of the gravity environment. 
FIG. 4 is a photomicrograph at enhanced magnification 
over that of FIG. 3A and B showing details of certain 
microcapsules of the invention when practiced at unit grav- 
ity. A single large microcapsule 50 and several smaller ones 
52 are shown. Nested inside microcapsule 50 can be seen 
several oil solvent spheroids (olive oil) 51 each of which is 
surrounded by the inner aqueous layer 54. Aouter polymeric 
coating 56 can be seen on microcapsules 50 and 52. It is also 
possible to detect 3-4 spherical shells 58 nested within one 
another on certain of the smaller microcapsules 60. FIG. 5 
is a photomicrograph of a microcapsule formed under 
microgravity of the invention which was made with a 
fluorescent dye in order to demonstrate the ability of the 
microcapsules of the invention to segregate a drug into a 
distinct layer. FIG. 5A shows a single microcapsule 70 in 
focus without using fluorescence microscopy comprising a 
outermost polymeric coating 72, an internal hydrocarbon 
solvent phase 74, a second polymeric membrane 76, aque- 
ous spheroids 78 contained within the hydrocarbon inner 
layer 74, and an aqueous shell layer 80. FIG. 5B shows the 
result when the same microcapsule was photographed using 
a light source and optics to enable visualization of the 
fluorescent dye location, the internal spheroids 78 and 
aqueous shell or layer 80 are seen to fluoresce to indicate the 
location of the dye 82 therein. 
FIG. 6 depicts the capacity of the methods of the inven- 
tion to create spherical microcapsules of uniform and sub- 
stantial volumes which are capable of forming crystalline 
structures in their internal layers or shells. FIG. 6A shows a 
microcapsule 90 with a single cubic crystal of Cis-platinum 
92 trapped within. FIG. 6B shows a microcapsule 94 with 
numerous crystals of Cis-Platinum 96 formed within. 
FIG. 7 shows a collection of microcapsules 110 of the 
invention which have been treated to contain a radio- 
contrast oil (iodinated poppy seed oil) 100 and crystals of 
Cis-Platinum 102 contained in microcapsules 104 with 
uniform spherical shells 106 and an outer polymeric coating 
108. 
EXAMPLE I 
MICROGRAVITY EXPERIMENTS SUMMARY 
The basic formulations and simplified liquid-liquid, dis- 
persion methods were developed in 1988 and 1989. The 
conceptual approach is shown in FIG. 1.  FIG. 1 is a 
schematic showing formation of a multi-lamellar microcap- 
sule with an aqueous drugioil dispersion at its center, a 
5,827,531 
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hydrocarbonioil drug#2 and/or radiocontrast medium (e.g. 
IPO) as a next layer, an aqueous layeridrug (e.g., cis- 
platinum) as a next layer, and a polymeric outer coating or 
skin. Microencapsulation-related experiments designed to 
overcome the limitations of the first methods were con- 
ducted on six space missions beginning in April 1989 with 
the Consort-I sounding rocket using the Materials Disper- 
sion Apparatus (MDA) mini-lab developed by Instrumenta- 
tion Technology Associates, Inc. The sounding rocket flights 
produced only 6.5 minutes of microgravity conditions, but 
this was adequate to form the unique microcapsules in a 
single step. Experiments on the Space Shuttle permitted 10 
minute dispersion times followed by curing of the outer 
polyglyceride skin for eight days under microgravity con- 
ditions. A summary of these experiments is shown in Table 
2. New formulations were tested on Shuttle STS-52, using 
only aqueous-soluble drugs, polymers and surfactants, and 
on STS-56 using alcohols as co-surfactants. The specific 
experiments and results are described in detail in the 
examples to follow. 
TABLE 2 
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produced unique multi-lamellar microcapsules containing 
various aqueous drugs co-encapsulated with iodinated 
poppy seed oil (a radiocontrast medium with a sp. gravity= 
1.35). Subsequent ground control experiments also pro- 
s duced some of these unique microcapsules and illustrated 
that the l x g  process could be improved to yield usable 
microcapsules by using different formulations. In particular, 
it became clear that the outer coatings substantially 
improved the ruggedness of the microcapsules formed. 
10 
EXAMPLE I11 
SOUNDING ROCKET EXPERIMENTS 
Initial experiments on Consort-1 and -3 were used to 
IS determine the effective mixing and diffusion kinetics in the 
MDAs (see below for apparatus description). This showed 
that sufficient volume was mixed at the interface via diffu- 
sion to allow formation of microcapsules. These experi- 
ments also provided the diffusion constants for each of the 
components of the liquid phases. 
MED Flight Experiments Summarv 
MISSION aDATE EXPERIMENTS MATERIALS RESULTS 
Consort-1 4/89 protein diffusion 
Consort-1 3/90 diffusion kinetics 
Consort-4 11/91 microencap- 
sulation of drugsab 
Consort-5 9/92 microencap- 
sulation of drugsab 
STS-52 10192 microencap- 
sulation of drugs 
(aqueous polymers 
only)ab 
STS-56 4/93 microencap- 
sulation of drugs 
(alcohol co- 
surfactants)ab 
urokinase & antibodies 
urokinase & 
myoglobin 
Cis-Platinum, 
amoxicillin, urokinase 
& Strept-avidin 
Cis-platinum, 
amoxicillin & 
urokinase 
Cis-platinum, 
amoxicillin & 
urokinase 
diffusion rates 
established 
kinetics verified 
multi-lamellar microspheres w/ 
alternating hydrophilic & 
hydrophobic layers 
multi-lamellar microspheres w/ 
alternating hydrophilic & 
hydrophobic layers 
multi-lamellar microspheres, 
crystals within microcapsules 
Cis-platinum, multi-lamellar microspheres, 
amoxicillin & crystals within microcapsules 
urokinase 
aFluorescent labels included 
bFluorescent beads included 
4s  
EXAMPLE I1 The first successful microencapsulation of drugs in micro- 
gravity was conducted on the Consort-4 mission in Nov. 
1991. The microcapsules were recovered and analyzed by 
microscouic image analvsis. Mono-disuersed fluorescent 
GRAVITY-DEPENDENT RESTRICTIONS 
RECOGNIZED 
I
Gravity-dependent restrictions in the basic liquid-liquid 50 beads were included as internal size standards and fluores- 
spontaneous microencapsulation process led to the design of cent labels were used to determine the distribution of drug 
several microgravity experiments to explore the utility of in the various fluid compartments. Additional experiments, 
this process when density-driven phenomena were elimi- conducted on Consort-5 in September 1992, confirmed the 
Dated. In particular, density-driven, gravity-dependent capabilities of the new method for forming multi-lamellar 
restrictions of the liquid-liquid microencapsulation process 5s microcapsules with alternating layers of hydrophilic and 
were: early phase separation producing fragile microcap- hydrophobic drugs. 
sules; interfacial dynamic flow causing coalescence of Microcapsules formed in 38 microgravity mini- 
microcapsules. Failure of ground-based experiments to experiments used liquid-liquid dispersion of aqueous drug 
derive uniform microcapsules lead to a desire to attempt solutions, surfactant and polyethylene glycol dispersed in 
microcapsule formation in space. 60 alcoholic co-surfactant solutions containing soluble polyg- 
The microgravity flight experiments led to the develop- lycerides. 
ment of a new liquid-liquid microencapsulation process that Microcapsules of both oiliwater and polymeriwaterioil 
involves use of surfactants and co-surfactants in the aqueous were recovered from the Consort flights. These experiments 
phase and co-surfactant alcohols in the organic phase, which produced multi-lamellar liquid microcapsules (concentric 
also contained, in one embodiment, high molecular weight 65 spheres within spheres) comprised of three or more, alter- 
polymers that formed a tough outer “skin” on the final nating immiscible layers. Image analysis of the microcap- 
microcapsules. In microgravity, a single step dispersion sules was made possible by co-encapsulation of standard 
5,827,531 
23 
size fluorescent beads. Microcapsules were formed in the 
ranges of 1-15 microns, 40-50 microns, 110-130 microns 
and 160-230 microns in diameters. This was a substantial 
improvement over the prior art approaches which had ini- 
tially been attempted by the inventors to derive microcap- 
sules only in the 10 micron and less-range. The size distri- 
bution covered a range of from about as low as 5 microns in 
diameter up to about 300 microns in diameter and greater. 
The average size of the microcapsules formed in these 
experiments was about 150 microns, greatly in excess of the 
average 10 micron or less diameters obtained with prior art 
approaches. 
The ruggedness of the microcapsules formed under these 
conditions allowed for size segregation by sieving. Digital 
analysis (National Institutes of Health image analysis 
program) of phase contrast and fluorescent images taken 
with a fluorescent microscope also confirmed that the 
aqueous-soluble drugs were routinely encapsulated within 
the inner aqueous core and the outermost aqueous shell of 
the microcapsules. 
This typical distribution is illustrated in FIG. 5,  which is 
a composite of a transmitted light photomicrograph and a 
fluorescent photomicrograph (lower right) of the same 
multi-lamellar microcapsule. The polyglyceride skin is 
clearly shown in the normal-light photomicrograph (upper 
left). 
Multi-lamellar microcapsules were, also formed which 
contained relatively large amounts of IPO (Guerbet Labo- 
ratories - France, Savage Laboratories - U.S.A.) in discrete 
lamella. FIG. 7 shows a microcapsule heavily loaded with 
IPO, which often comprised up to 38% of the total volume. 
Often small hemispheres of IPO were also found clinging to 
the outer surface of the large inner (aqueous) sphere or 
adhered to the outer polymer skin of the microcapsule. 
Microcapsules formed by almost all of the formulations 
survived 15+g accelerations, severe vibrations and turbulent 
mixing, during the reentry of the experiment capsule, and 
have remained intact for two years after recovery from 
space. These multi-layered microcapsules are similar to 
liquid-filled, thin-skinned, micro-balloons which are flexible 
enough to be manipulated on a microscope slide without 
collapse. 
The microcapsules formed in just 6.5 minutes of micro- 
gravity retain their spherical shape and appear tough enough 
to survive the extensive physical manipulations required for 
sizing, final preparation and storage of parenteral 
suspensions, and the fluid shear encountered after intravas- 
cular injection. 
Also formed were very unusual structures (multiple small 
spheres of aqueous-soluble drug) distributed within multi- 
lamellar o/w/o microcapsules, wherein the aqueous sphe- 
roids are arranged in an annular ring that appears fixed in a 
plane within the innermost sphere (not shown). These ring 
structures remain intact when the microcapsules are “rolled 
around” on the microscope slide without rupturing. These 
structures demonstrate the ability of the methods of the 
invention to form small spheroids that do not coalesce inside 
the larger microcapsule. Such structures may be advanta- 
geously used to control the specific volume to surface area 
ratio in order to control the rate of diffusion of a solute in 
such spheroids. In particular, sustained release of pharma- 
ceuticals contained in such spheroids within microcapsules 
may find utility. 
EXAMPLE IV 
SPACE SHUTTLE EXPERIMENTS 
Microencapsulation experiments on Consort 4 and Con- 
sort 5 used mixtures of aqueous-soluble drugs, IPO, C3-C8 
24 
alcohols and polyglycerides that are insoluble in aqueous 
solutions. In experiments conducted on STS-52, the inven- 
tors co-encapsulated cis-platinum (diaminodichlor-cis- 
platinum; Bristol Laboratories) with IPO by forming micro- 
5 capsules from water-soluble polymers using special 
formulations of aqueous, non-alcoholic solvents. Such for- 
mulations will find particular utility in co-encapsulations of 
anti-tumor compounds along with radiocontrast medium for 
tracking drugs in the body. 
Polyvinyl pyrolidone (PVP) and a commercial lethicin 
(Centrolex-FTM; a lecithins compound produced by U.S. 
Soya, Inc.) were used to form multi-lamellar microcapsules 
at 20” C. Fluorescent beads and fluorescent labeled were 
co-encapsulated with the drugs to permit drug-distribution 
15 measurements, within the various lamellae, using fluores- 
cence microscopy and digital image analysis at the NASA 
Johnson Space Center, Houston, Tex. The final microcap- 
sules were suspended and recovered in either aqueous 
solutions, IPO or mineral oil. The microcapsules formed by 
2o these formulations were similar to those made using alcohol- 
soluble polyglycerides. However, without the hydrocarbon- 
soluble polyglyceride skin these microcapsules were more 
fragile. 
Another unique type of microcapsule was formed during 
25 these experiments that was characterized by drug crystals 
formed within the inner aqueous core of the multi-lamellar 
microcapsules. FIG. 6B shows an example of a microcap- 
sule which is packed (approximately 65% of the aqueous 
compartment) with crystals of Cis-platinum, an anti-tumor 
30 drug. Microcapsules containing crystals of amoxicillin were 
also formed in the STS-52 experiments (not shown). These 
illustrate that aqueous-soluble drugs can be encapsulated at 
very high concentrations near the solubility limit of the drug. 
After the microcapsules are formed the drug can become 
35 further concentrated (perhaps via the alcohol absorbing the 
water from the aqueous phase in which the pharmaceutical 
solute is dissolved) to form large crystals which are more 
stable than the dissolved drug during prolonged storage. 
Microcapsules formed from first organic solventipolymer 
40 methods appeared to be more rugged (by visual comparison 
under the microscope) than those formed on STS-52 formed 
from first solvent aqueousipolymer methods. The STS-56 
experiments again produced multi-lamellar liquid microcap- 
sules (multiple concentric spheres within spheres) com- 
45 prised of alternating immiscible layers. Using fluorescent 
6.4 micron beads and image analysis, it was found that the 
most interesting microcapsules were formed in the range of 
l e 1 5  micron, 40-50 micron, 50-100 micron, and 1 6 e 2 3 0  
micron diameters. These diameter distributions were of 
50 particular interest since it is known that intraarterial uses can 
accommodate 50-300 micron diameter microcapsules while 
intravenous applications can only tolerate 1-10 micron 
microcapsules. Thus, by segregating the microcapsules into 
sized fractions (sieving), it should be possible to address 
As noted above, microcapsules were formed containing 
crystals of cis-Platinum or amoxicillin. The crystals appar- 
ently were formed after encapsulation. Several microcap- 
sules were formed that contained a single, large cubic crystal 
60 of Cis-Platinum which so completely filled the inner sphere 
that only about 15% of the inner volume remained as a 
liquid. One encapsulated, cubic Cis-Platinum crystal was 
measured at 48p across within a 57p diameter microcapsule 
(similar to that shown in FIG. 6A). After formation, some of 
65 the microcapsules were dispersed in an external oil phase 
(either IPO or mineral oil) and allowed to cure for eight days 
before return to Earth. 
5s particular intravascular limitations. 
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These microgravity experiments have shown that forma- solvent compartments is strongly dependent on the interfa- 
tion of multi-lamellar, alternating-phase microcapsules can cial tension and the amount of mixing between immiscible 
be controlled by proper timed-sequence exposures of the liquid phases. On Earth this process is limited by gravity- 
immiscible phases using special solvent formulations and dependent, density-driven separation of the immiscible liq- 
surfactants. Once formed, these microcapsules remain s uids into stratified horizontal layers. In microgravity, this 
spherical due to the predominant surface tension of the process is largely dependent on the surface-free energies of 
internal phases and polymerisolvent phase partitioning at the the different liquids, but independent of density-driven con- 
interfaces. vection or buoyant phase separation. Hydrocarbon soluble, 
These experiments clearly demonstrated the capability to high molecular weight Polymers have been included in the 
use 1iqu&liquid diffusion mixing to form unique microcap- 10 formulations to form flexible, permeable “skins” or outer 
containing hydrophilic and hydrophobic drugs under coatings around the liquid microcapsules as they are created 
microgravity conditions, Thus, ground-based experiments by phase partitioning mechanisms. It is also possible to form 
were conducted to compliment and replicate the space such polymer barriers between internal layers. The micro- 
experiments. These ground-based experiments were able to capsules can be formed and cured without deformation by 
replicate the size range (5-250 microns in diameter) to a 1s contact with container walls. 
limited degree, but the average size microcapsule obtained More specifically, co-encapsulation of an aqueous- 
was about 1 0 4 0  microns in diameter. Still, this was a soluble, anti-tumor drug (Cis-platinum) and a radio-contrast 
substantial improvement over the prior art approaches which medium (IPO), in microgravity, has produced a unique drug 
rarely formed microcapsules over 10 microns in diameter. It delivery system that can be visualized by radiologic or 
was also observed that the ground-based experiments 20 computerized tomography scanning to insure that the cyto- 
resulted in less rugged microcapsules. This is likely a result toxic drug is delivered directly to the target tumor. Multi- 
of the gravity-dependent deformations of the spherical layered microcapsules have been developed which can pro- 
microcapsules as they form giving rise to areas of thinner vide a new intravascular delivery system for targeted tissues 
polymer deposition. Thus, the flexible microcapsules, and sequential, sustained release of multiple anti-tumor 
formed under microgravity conditions, have more uniform 2s drugs. This method has resulted in formation of flexible 
size distributions than those formed in lxg, are more rugged, spherical microcapsules of more uniform sizes, which can 
and have a higher average diameter than ground-made provide maximum packing densities and maximum drug 
microcapsules, largely due to the absence of thermal delivery to target organs or tumors. 
es that occur at 
the immiscible interfaces. 30 active forms of urokinase and other thrombolytic enzymes 
The microgravity experiments illustrate the feasibility of until they are delivered and entrapped at the local site of a 
co-encapsulating aqueous-soluble drugs, hydrocarbon- blood clot, where therapeutic doses of the enzyme can 
soluble drugs and oil-based contrast media within a lipid- diffuse out to dissolve the unwanted embolism. These 
soluble, polyglyceride outer film which cures rapidly immiscible-liquid diffusion methods also could be used for 
enough to be impervious to oil or hydrocarbon resolubili- 3s encapsulating certain labile drugs to make microcapsules for 
convection, buoyancy forces, and instab Multi-layered microcapsules can be designed to protect 
zation. They also allow the formation and harvesting of 
unique microcapsules which are durable enough to be 
removed from the external solvent without disruption or 
destruction of the internal phases. It is anticipated that these 
microcapsules will have several advantages over conven- 
tional liposomes that are designed for intravascular injec- 
tion. 
EXAMPLE V 
FLIGHT HARDWARE DESCRIPTION 
special purpose drug delivery systems, especially those 
designed to deliver drugs via the nasal or buccal mucosa or 
via inhalation directly to the lungs. Examples include pro- 
tected delivery of mucolytic DNAse for sustained release 
40 treatment of cystic fibrosis and a anti-trypsin for patients 
with deficiencies in the lung epithelium. 
EXAMPLE VI11 
4s REDISPERSION OF MICROCAPSULES IN 
AQUEOUS OR OIL VEHICLES 
The microencapsulation experiments described herein A frequently used second step includes dispersion of the 
were conducted using the Materials Dispersion Apparatus microcapsules (after they have formed) in different aqueous/ 
(MDA, ITA, Inc., Exton, Pa.). The MDA’s consist of an so polymer solvents or in a pure oil phase. A unique attribute 
upper and a lower block that contain chambers for each of microcapsules formed by these methods is that they do 
sample fluid. The blocks are misaligned at launch so that the not re-dissolve in an oily external phase, even though the 
chambers are not in contact with each other. Upon activation semi-permeable outer skin is hydrophobic. This produces a 
in microgravity, the blocks are moved to align the chambers suspension in the liquid carriers that are commonly used 
so that the fluids, can mix by liquid-liquid diffusion. Some 5s for,intravascular administration. 
of the experiments were conducted with a single-step fluid 
mixing, and some were done with a two-step fluid mixing EXAMPLE IX 
technique which allows diffusion of a third fluid or sample 
into the mixture of the first two fluids while still in the EXEMPLARY FIRST ORGANIC SOLVENT 
MICROCAPSULE FORMULATIONS microgravity environment. 60 
EXAMPLE VI 
The following formulations have been used with particu- 
lar success by the inventors in both earth normal and 
microgravity methods of making microcapsules. 
Fluid 1-(hydrocarbon) DISCUSSION AND ALTERNATIVE EMBODIMENTS 
65 The first solvent is a hvdrocarbon fluid (ethvl alcohol. 
\ a  
Spontaneous formation of multi-lamellar, microcapsules 
containing alternating layers of aqueous and hydrophobic 
methyl alcohol, or isopropyl alcohol) with a low or medium 
HLB (HLB=5-10). One or more co-solvents are used (which 
5,827,531 
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also can act as co-surfactants). Small concentrations of oil 
and water are added. Into this mixture, the mono- or polyg- 
lyceride is dissolved up to 5% w/v. An example is: Alternate concentrations: 
88% IPA 
2.5% m-Hexanol 
2.5% n-Heptanol 
5% IPO 
Fluid 1: Main solvent 75-95% 
5 Co-solvents 1-10% 
Oil 1-10% 
Polymer 
Water 
1-5% 
1-20% 
2% H,O 
5% GMS 
10 Alternate composition for Fluid 2 
PEG 200-10000 
Fluid 2 (aqueous) Dextran-40 (MW=40,000-70,000) 
The second solvent is water plus surfactants (ex. poly- 
ethoxylated sorbitan esters; Polyethylene glycol). APolYsac- 
charide (Dextran) and normal saline (0.9%) are added which 
helps achieve the desired critical micelle concentration. A 
pharmaceutical soluble in water is added. An example is: 
0.9% Sodium chloride 
Sorbitan Monolaurate/20 moles Ethylene oxide 
balance is water 
Drug dissolved at saturated or specified 
1% PEG 4000 
5% Dextran-40 (MW=40,000) 
concentration 
(according to required dose and release rate) 
20 
0.9% Sodium chloride 
2% Sorbitan Monooleate/20 moles Ethylene oxide 
Alternate concentrations: 
1-5% 
5-10% 
0.9% 
PEG 
Dextran (MW = 40,000-70,000) 
2s  Sodium chloride 
Sorbitan Monolaurate/20ETO 1-5% 
Water (balance of volume) 
Drug concentration saturated or specified 
Water (up to 100% volume) 
dissolved drug at specified concentration 
(according to required dose and release rate) 
Fluid 3 (oil) 
An oil, immiscible with the first two fluids in which the 
microcapsule’s “outer skin” is insoluble so that the sus- 30 Alternate composition for Fluid 3 (Oils) 
pended microcapsules can be delivered by injection when 
non-aqueous administration is required. Submersion of 
microcapsules in the oil also can aid the curing or polymer- 
ization of the ‘‘outer skin.” A preferred example of the oil 
vehicle is iodinated poppy seed oil which also serves as a 35 Alternate concentrations 
radiocontrast medium. 
Dense radiocontrast liquids s.a. iodinated unsaturated oils 
e.g. poppy seed oil, cotton seed oil, safflower oil, olive oil, 
canola oil, peanut oil, sesame oil, corn oil. 
Also saturated oils can be used, s.a. heavy mineral oil 
100% oil or a mixture is used as a carrier vehicle for the 
suspended microcapsules 
Alternate compositions for Fluid 1 
Main solvent--ethyl alcohol 40 
Co-solvents-(co-surfactants) are normal alcohols-C4 
to 
C8 
high dielectric constant solvents 
4s tetrahydrofuran 
dioxane 
acetonitrile 
dimethylformamide 
dimethylacetamide 
dimethylsulfoxide so 
Oil-dense radiocontrast liquids s.a. iodinated unsatur- 
ated oils 
e.g. poppy seed oil, cotton seed oil, safflower 
oil, olive oil, canola oil, peanut oil, sesame 
oil, corn oil. 
also saturated oils can be used, s.a. heavy mineral oil, 
Polymers-used to form the “outer skin” on the micro- 
55 
liquid petrolatum 
capsules monoglycerides-esp. glycerol esters ranging 60 
from C12-C22, 
e.g. monostearate, distearates, monooleates, monolau- 
polyglycerides-cholesterol,  waxy plant s terols  
(stigmasterol, phytosterol, campesterol) phospholipids- 65 
lecithins (phosphatidyl choline) and/or combinations with 
monoipolyglycerides 
rates and olive oil 
EXAMPLE X 
EXEMPLARY FIRST AQUEOUS SOLVENT 
MICROCAPSULE FORMULATIONS 
ALTERNATE METHOD-Hydrophilic Outer Skin 
Fluid lgaqueous) ;  the main solvent is a water, one or 
more co-solvents (which also can act as co-surfactants), 
and a lecithins is dissolved up to 5% w/v to form the 
outer skin on the microcapsules. 
An example is: 
3% polyvinyl alcohol dissolved in a mixture of 
20% isopropyl alcohol and 
80% water 
Fluid 2 (aqueous); the main solvent is water plus surfac- 
tants (ex. polyethoxylated sorbitan esters; polyethylene 
glycol) and plus a polysaccharide (Dextran) and normal 
saline (0.9%) which helps achieve the desired critical 
micelle concentration. 
An example is: 
1% PEG 4000 
5% Dextran-70 (MW=-70,000) 
0.9% Sodium chloride 
2% Sorbitan Monooleate/20 moles Ethylene oxide 
Water (up to 100% volume) 
dissolved drug at saturated or 
5,827,531 
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specified concentration 
(according to required dose and release rate) 
Fluid 3 (aqueous)-a PEG and PVP solution which can aid 
the curing or polymerization of the “louter skin.” 
1% Polyvinyl pyrolidone 
4% PEG 4000 
5% Dextran-70 (MW=-70,000) 
balance is 0.9% Sodium chloride 
REFERENCES CITED 
The following references to the extent that they provide 
details supplementary to those set forth herein, are specifi- 
cally incorporated herein by reference. 
Allen, T. M.. Interactions of Drug Carriers with the Mono- 
nuclear Phagocytic System, in G. Gregoriadis (Ed.) Lipo- 
somes as Drug Carriers, John Wiley & Sons Ltd., New 
York, pp.37-50, 1988. 
Allen, T. M., Mehra, T., Hansen, C. and Chin, Y. C., Stealth 
Liposomes: An Improved Sustained Release System for 
1-b-D-Arabinofuranosylcytosine, Cancer  Res .  
Bhargava, H. N., Narurkar, A,, and Lieb, L. M., Using 
Microemulsions for Drug Delivery, Pharmaceutical 
Technology, pp. 46-54, Mar. 1987. 
Gabizon, A,, et al., Liposome-Associated Doxorubicin: Pre- 
clinical Pharmacology and Exploratory Clinical Phase, in 
G. Lopez-Berestein and I. J. Fidler (Eds.) Therapy of 
Infectious Diseases and Cancer, Alan R. Liss, Inc., New 
York, pp. 189-203, 1992. 
Halbert, G. W. , Stuart, J. B., Florence, A. T., The Incorpo- 
ration of Lipid Soluble Antineoplastic Agents into 
Microemulsions-Protein-free Analogues of Low Density 
Lipoprotein, Int. J. Pharm. 21: 219-232, 1984. 
Kimler, B. F, et al., Combination of Aziridinylbenzoquinone 
and Cis-platinum with Radiation Therapy in the 9L Rat 
Brain Tumor Model, Int. J. Radiation Oncology Biol. 
McCutcheon’s Detergents and Emulsifiers, 1979, North 
American Edition, McCutcheon Division, MC Publishing 
Co., 175 Rock Road, Glen Rock, N.J. 07452. 
“Specifically, for HLB values ranging from 2 to 42 , see 
pages 29-39, and for HLB values ranging from 0.5 to 
30.5, see pages 228-241.” 
Parikl, 1. and Stern, W. Microcrystal’” Drug Delivery 
System, in Harvey S. Price (Ed) The Biotechnology 
Report 1993194, Bookbuilders, Ltd., Hong Kong, pp. 
Talsma, H. and Crommelin, D. J. A,, Liposomes as Drug 
Delivery Systems, Part 1: Preparation. Pharmaceutical 
Technology, pp. 96-106, October 1992. 
Wright, K. C., Wallace, S., Mosier, B. and Mosier, D., 
Microcapsules for Arterial Chemoembolization: Appear- 
ance and In Vitro Drug Release Characteristics, J. 
Microencapsulation 5:13-20, 1988. 
The present invention has been described in terms of 
particular embodiments found or proposed to comprise 
preferred modes for the practice of the invention. It will be 
appreciated by those of skill in the art that, in light of the 
present disclosure, numerous modifications and changes can 
be made in the particular embodiments exemplified without 
departing from the intended scope of the invention. For 
example, one alternate embodiment includes use of 
aqueous-soluble cyclodextrin (in the hydrophilic phase) 
which has hydrophobic center that can itself entrap hydro- 
phobic drugs,thereby acting as a carrier for hydrophobic 
drugs within the aqueous phase. Another alternate embodi- 
5212431-39, 1992. 
Phys, 26: 445-450, 1993. 
219-220, 1994. 
30 
ment allows after microcapsules are formed, for ancillary 
polymeric outer coats to be applied by conventional methods 
(electrostatic coating, aerosolization and drying, etc.). This 
is made possible by designing the precise chemical makeup 
s of the initial polymeric outer skin such that it will be 
compatible with both drug diffusion and the ancillary coat- 
ing to be applied. When surfactants are used to facilitate 
adhesion of the third solution or ancillary coating the HLB 
must be selected to be compatible with the HLB of the 
i o  existing outer coating which has already been formed, such 
that the solution containing the ancillary coating will wet the 
surface of the existing outer coating, to enable deposition of 
the ancillary coating. This is in contrast to conventional 
liposomes whose outer membrane composition is a variable, 
is depending on the phase separation of the phospholipids and 
cholesterol adduct when each liposome forms. Another 
alternative embodiment incorporates an energy absorbing 
medium ( e.g.  photoactivator) which can absorb 
electromagnetic, ultraviolet, infrared, ultrasonic, radiofre- 
20 quency and microwave radiation and thereby cause activa- 
tion of a short-lived drug component just prior to adminis- 
tration or after the microcapsules have reached the target 
site. Another embodiment incorporates magnetic particles 
and magnetic fields or free-fluid electrophoretic 
zs mechanisms, etc. to facilitate dispersion or transport of one 
phase across the immiscible interface into the other phase. 
This has been demonstrated as a single pass, uni-directional 
form of mixing that is best exploited in microgravity. 
Another embodiment includes attachment of certain 
30 (hydrophobic) antibodies to the polymeric skin which gives 
the microcapsules site specificity by being able to bind to 
target cells (e.g. tumor) while entrapped drugs diffuse out to 
provide maximum doses to those cells with that antigenic 
site. Another embodiment makes use of polyethylene glycol 
35 (PEG) complexed to peptide or protein drugs and a custom- 
ized polymeric outer skin which permits the drug-PEG 
complex to diffuse out of the microcapsule as an intact 
entity. This permits the drug to resist antibody attachment 
and remainsin the blood stream longer as found in the 
type of drug complexes developed by Enzon, 
Inc. The improvement being delivery of this complex in the 
tailored microcapsules and controlled release of the complex 
through the specially designed polymeric outer skin. All 
such modifications are intended to be included within the 
40 Pegnology 
45 scope of the appended claims. 
What is claimed is: 
1. A method of making a multi-layered microcapsule, 
formulating a first phase comprising a first solvent, a first 
microcapsule layer-forming compound soluble in said 
first phase and immiscible in a second phase, a 
co-solvent, oil, and water; 
formulating said second phase immiscible with said first 
phase, said second phase comprising a second solvent, 
a second microcapsule layer-forming compound 
soluble in said second phase and immiscible in said first 
phase, a surface active agent, and a salt; 
said surface active agent having a hydrophilicilipophilic 
balance value greater than that of said first microcap- 
sule layer-forming compound; 
said second microcapsule layer-forming compound hav- 
ing a hydrophilicilipophilic balance value lower than 
that of said surface active agent; 
creating an interface between said first and second phases 
in a manner that limits fluid shear equal to or less than 
about 12 dynesicm’ , and 
comprising: 
50 
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maintains adsorptive surface characteristics at said inter- 
2. The method of claim 1 wherein said first solvent is 
organic. 
3. The method of claim 2 wherein said organic solvent is 
selected from the group of organic solvents consisting of 
methyl alcohol, ethyl alcohol, and isopropyl alcohol. 
4. The method of claim 1 wherein said first microcapsule 
layer-forming compound is selected from the group consist- 
ing of glycerol monosterate, glycerol monooleate, glycerol 
monolaurate, glycerol dioleate, glycerol distearate, 
cholesterol, stigmasterol, phytosterol, campesterol, polyvi- 
nyl pyrrolidone, polyvinyl alcohols, hydrocolloids, and leci- 
thins. 
5. The method of claim 1 wherein said first solvent is 
aqueous. 
6. The method of claim 4 wherein said hydrocolloid is 
selected from the group of hydrocolloids consisting of 
gelatin, gum tragacanth, carrageenan, Karaya gum, Guar 
gum, gum arabic, alginates, carboxymethyl cellulose, 
hydroxypropyl cellulose, and carboxypropyl cellulose. 
7. The method of claim 1, said first phase further com- 
prising a co-solvent, wherein said co-solvent is selected 
from the group of co-solvents consisting of C,-C, alcohols, 
tetrahydrofuran, dioxane, acetonitrile, dimethylformamide, 
dimethylacetamide, and dimethyl sulfoxide. 
8. The method of claim 1 wherein said oil is selected from 
the group of oils consisting of poppy seed oil, olive oil, 
peanut oil, sesame oil, cotton seed oil, soybean oil, safflower 
oil, corn oil, sunflower seed oil, canola oil, mineral oil, 
C,,-C,, paraffinic oil, and liquid petrolatum. 
9. The method of claim 1 wherein said oil is an unsatur- 
ated oil which has been halogenated. 
10. The method of claim 1 wherein said second micro- 
capsule layer-forming compound is selected from the group 
consisting of polyethyleneglycol, polyvinylpyrrolidone, 
polyvinyl alcohols, and hydrocolloids. 
11. The method of claim 1 wherein said surface active 
agent has a hydrophilicilipophilic balance value of about 
10.0 or greater. 
12. The method of claim 11 wherein said surface active 
agent is selected from the group of surface active agents 
consisting of sorbitan monooleate treated with ethylene 
oxide, dextran, polyethylene glycol, C,,-C,, fatty acids, 
2-amino-2-methyl-l-propyl aminomethyl propanol ampho- 
teric salts, and quaternary ammonium salts. 
13. The method of claim 1 wherein said salt is selected 
from the group of salts consisting of NaC1, KC1, CaCl,, 
MgCl,, quaternary ammonium salts, cetyl trimethylammo- 
nium bromide, and 4-methoxy-4(3-phosphatidyl choline) 
spiro(l,2-dioxetane-3-g,l-adamantane) disodium salt. 
14. The method of claim 1 wherein said first phase further 
comprises a pharmaceutical composition. 
15. The method of claim 14 wherein said pharmaceutical 
composition is selected from the group of pharmaceutical 
compositions consisting of cytotoxins, proteases, cytokines, 
anti-nauseants, steroids, anti-fungal agents, fibrinolytic 
enzymes, and antibiotics. 
16. The method of claim 14 wherein said pharmaceutical 
composition is in suspension. 
17. The method of claim 1 wherein said second phase 
further comprises a pharmaceutical composition. 
18. The method of claim 17 wherein said pharmaceutical 
composition is selected from the group of pharmaceutical 
compositions consisting of cytotoxins, proteases, cytokines, 
anti-nauseants, steroids, anti-fungal agents, fibrinolytic 
enzymes, and antibiotics. 
face. 
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19. The method of claim 17 wherein said pharmaceutical 
composition is in suspension. 
20. The method of claim 14 wherein said pharmaceutical 
is at a concentration sufficient to allow nascent crystal 
21. The method of claim 1, wherein after said microcap- 
formulating a third phase comprising an oil or C,,-C,, 
contacting said microcapsule with said third phase. 
22. The method of claim 21, wherein said third phase 
23. The method of claim 21, wherein said third phase 
24. The method of claim 1, wherein after said microcap- 
formulating a third phase comprising an aqueous solution; 
contacting said microcapsule with said third phase. 
25. The method of claim 24, wherein said third phase 
further comprises a pharmaceutical composition. 
26. The method of claim 24, wherein said third phase 
further comprises an adjuvant. 
27. The method of claim 24, wherein said third phase 
further comprises an activator agent. 
28. The method of claim 26, wherein said adjuvant further 
comprises an immunoglobulin, peptide, protein, hydrocol- 
loid or polysaccharide. 
29. The method of claim 28, wherein said hydrocolloid is 
selected from the group of such hydrocolloids consisting of 
collagen, isoelectric gelatin, agar, gum arabic, gum 
tragacanth, carboxymethylcellulose (CMS), carboxymethyl/ 
ethyl cellulose (CMEC), hydroxyethylcellulose (HEC), 
35 hydroxymethyliethyl cellulose (HMEC), hydroxypropyl cel- 
lulose (HPC), alginates and carrageenans. 
30. The method of claim 24, wherein said third phase 
further comprises a surface active agent compatible with the 
hydrophilicilipophilic balance value of an outer coating of 
31. The method of claim 1 wherein one or more of said 
phases further comprise fluorescent molecules selected from 
the group of fluorescent molecules consisting of 
fluoresceins, cyanins, naturally fluorescent molecules, and 
32. The method of claim 1 wherein said adsorptive 
surface characteristics comprise a Helmholtz charge distri- 
bution at said interface. 
33. The method of claim 1 wherein said maintenance of 
so adsorptive surface characteristics is promoted by carrying 
out the method under microgravity of less than or about 
equal to lxlO-'g and with fluid shear of no more than 
between about 2-12 dynesicm'. 
34. The method of claim 33 wherein said microgravity is 
55 at least 1.0 minute in duration. 
35. The method of claim 1 wherein said maintenance of 
adsorptive surface characteristics is promoted by carrying 
out the method below ambient temperature. 
36. The method of claim 1 wherein said maintenance of 
60 adsorptive surface characteristics is promoted by substan- 
tially balancing the specific gravity between said phases. 
37. A method of making a multi-layered microcapsule, 
comprising: 
formulating a first phase comprising an organic solvent 
selected from the group of organic solvents consisting 
of methyl alcohol, ethyl alcohol and isopropyl alcohol, 
a first microcapsule layer-forming compound soluble in 
s formation within said microcapsule. 
sule forms, taking additional steps comprising: 
paraffin; and, 
lo 
further comprises a polymer. 
further comprises a pharmaceutical composition. 
sule forms, taking additional steps comprising: 
and, 
2o 
25 
30 
40 said microcapsule. 
45 rhodamines. 
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said first phase selected from the group of polymers 
consisting of glycerol monosterate,  glycerol 
monooleate, glycerol monolaurate, glycerol dioleate, 
glycerol distearate,  cholesterol,  st igmasterol,  
phytosterol, campesterol, and lecithins, a co-solvent 
selected from the group of co-solvents consisting of 
C,-C, alcohols, tetrahydrofuran, dioxane, acetonitrile, 
dimethylformamide, dimethylacetamide, and dimethyl 
sulfoxide, an oil selected from the group of oils con- 
sisting of poppy seed oil, olive oil, peanut oil, sesame 
oil, cotton seed oil, soybean oil, safflower oil, corn oil, 
sunflower seed oil, canola oil, mineral oil, C,,-C,, 
paraffinic oil, liquid petrolatum, and water; 
formulating a second phase immiscible with said first 
phase, said second phase comprising water, a second 
microcapsule layer-forming compound soluble in said 
second phase selected from the group consisting of 
polyethyleneglycol, dextran, polyvinylpyrrolidone, 
polyvinyl alcohols, hydrocolloids, and lecithins, a sur- 
face active agent selected from the group consisting of 
sorbitan monooleate treated with ethylene oxide, 
dextran, polyethylene glycol, C,,-C,, fatty acids, 
2-amino-2-methyl-1-propyl aminomethyl propanol, 
quaternary ammonium salts, and a salt selected from 
the group of salts consisting of NaC1, KC1, CaCl,, 
MgCl,, quaternary ammonium salts, cetyl trimethylam- 
monium bromide, and 4-methoxy-4(3-phosphatidyl 
choline)spiro(l,2-dioxetane-3-g,l-adamantane) diso- 
dium salt; 
said surface active agent having a hydrophilicilipophilic 
balance value greater than that of said first microcap- 
sule layer-forming compound; 
said second microcapsule layer-forming compound hav- 
ing a hydrophilicilipophilic balance value lower than 
that of said surface active agent; 
creating an interface between said first and second phases 
in a manner that limits fluid shear to less than about 12 
dynesicm' , and 
maintains adsorptive surface characteristics at said inter- 
face. 
38. Microcapsules produced by any of the methods of the 
preceding claims. 
39. The microcapsules of claim 38 wherein said micro- 
capsules are of a uniform distribution of diameters. 
40. The microcapsules of claim 39 wherein said diameter 
distribution is in a range of about 1.0 to 350.0 microns. 
41. The microcapsule of claim 38 further comprising at 
least one nascent crystal of a pharmaceutical composition. 
42. The microcapsules of claim 41 wherein said crystal 
occupies at least about 10 percent of the volume of said 
microcapsule. 
43. A microcapsule produced by the method of claim 37. 
44. A multi-layered microcapsule, comprising: 
a first layer comprising a first solvent, a first microcapsule 
layer-forming compound soluble in said first layer and 
immiscible with a second layer, a co-solvent, oil, and 
water; 
said second layer immiscible with said first layer, said 
second layer comprising a second solvent, a second 
microcapsule layer-forming compound soluble in said 
second layer and immiscible with said first layer, a 
surface active agent, and a salt; 
said surface active agent having a hydrophilicilipophilic 
balance value greater than that of said first microcap- 
sule layer-forming compound; and, 
said second microcapsule layer-forming compound hav- 
ing a hydrophilicilipophilic balance value lower than 
that of said surface active agent. 
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45. The microcapsule of claim 44 wherein said first 
solvent is organic. 
46. The microcapsule of claim 45 wherein said organic 
solvent is selected from the group of organic solvents 
consisting of methyl alcohol, ethyl alcohol and isopropyl 
alcohol. 
47. The microcapsule of claim 45 wherein said first 
microcapsule layer-forming compound is selected from the 
group consisting of glycerol monosterate, glycerol 
monooleate, glycerol monolaurate, glycerol dioleate, glyc- 
erol distearate, cholesterol, stigmasterol, phytosterol, 
campesterol, and lecithins. 
48. The microcapsule of claim 44 wherein said first 
solvent is aqueous. 
49. The microcapsule of claim 48 wherein said first 
microcapsule layer-forming compound is selected from the 
group of microcapsule layerforming compounds consisting 
of polyvinyl pyrrolidone, polyvinyl alcohols, hydrocolloids, 
and lecithins. 
50. The microcapsule of claim 49 wherein said hydrocol- 
loid is selected from the group of hydrocolloids consisting of 
gelatin, gum tragacanth, carrageenan, Karaya gum, Guar 
gum, gum arabic, alginates, carboxymethyl cellulose, 
hydroxypropyl cellulose, and carboxypropyl cellulose. 
51. The microcapsule of claim 44, said first layer further 
comprising a co-solvent, wherein said co-solvent is selected 
from the group of co-solvents consisting of C,-C, alcohols, 
tetrahydrofuran, dioxane, acetonitrile, dimethylformamide, 
dimethylacetamide, and dimethyl sulfoxide. 
52. The microcapsule of claim 44 wherein said oil is 
selected from the group of oils consisting of poppy seed oil, 
olive oil, peanut oil, sesame oil, cotton seed oil, soybean oil, 
safflower oil, corn oil, sunflower seed oil, canola oil, mineral 
oil, C,,-C,, paraffinic oil, and liquid petrolatum. 
53. The microcapsule of claim 44 wherein said oil is an 
unsaturated oil which has been halogenated. 
54. The microcapsule of claim 44 wherein said second 
microcapsule layer-forming compound is selected from the 
group consisting of polyethyleneglycol,  dextran,  
polyvinylpyrrolidone, polyvinyl alcohols, gelatin, gum 
tragacanth, carrageenan, Karaya gum, Guar gum, gum 
arabic, alginates, carboxymethyl cellulose, hydroxypropyl 
cellulose, carboxypropyl cellulose, and lecithins. 
55. The microcapsule of claim 44 wherein said surface 
active agent has a hydrophilicilipophilic balance value of 
about 10.0 or greater. 
56. The microcapsule of claim 55 wherein said surface 
active agent is selected from the group of nonionic surface 
active agents consisting of sorbitan monooleate treated with 
ethylene oxide, dextran, polyethylene glycol, C,,-C,, fatty 
acids, 2-amino-2-methyl-1-propyl aminomethyl propanol, 
amphoteric salts, and quaternary ammonium salts. 
57. The microcapsule of claim 44 wherein said salt is 
selected from the group of salts consisting of NaC1, KC1, 
CaCl,, MgCl,, quaternary ammonium salts, cetyl trimethy- 
lammonium bromide, and 4-methoxy-4(3-phosphatidyl 
choline)spiro(l,2-dioxetane-3-g,l-adamantane) disodium 
salt. 
58. The microcapsule of claim 44 wherein said first layer 
further comprises a pharmaceutical composition. 
59. The microcapsule of claim 58 wherein said pharma- 
ceutical composition is selected from the group of pharma- 
ceutical compositions consisting of cytotoxins, proteases, 
cytokines, anti-nauseants, steroids, anti-fungal agents, 
fibrinolytic enzymes, and antibiotics. 
60. The microcapsule of claim 58 wherein said pharma- 
ceutical composition is in suspension. 
5,827,531 
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61. The microcapsule of claim 44 wherein said second 
layer further comprises a pharmaceutical composition. 
62. The microcapsule of claim 61 wherein said pharma- 
ceutical composition is selected from the group of pharma- 
ceutical compositions consisting of cytotoxins, proteases, 
cytokines, anti-nauseants, steroids, anti-fungal agents, 
fibrinolytic enzymes, and antibiotics. 
63. The microcapsule of claim 61 wherein said pharma- 
ceutical composition is in suspension. 
64. The microcapsule of claim 58 or 61 wherein said 
pharmaceutical is at a concentration sufficient to allow 
nascent crystal formation within said microcapsule. 
65. The microcapsule of claim 44 comprising a third 
layer, said third layer comprising an oil or paraffin. 
66. The microcapsule of claim 65, wherein said third layer 
further comprises a pharmaceutical composition. 
67. The microcapsule of claim 65, wherein said third layer 
further comprises a surface active agent. 
68. The microcapsule of claim 44 comprising a third 
layer, said third layer comprising an aqueous solution. 
69. The microcapsule of claim 68, wherein said third layer 
further comprises a pharmaceutical composition. 
70. The microcapsule of claim 68, wherein said third layer 
further comprises an adjuvant. 
71. The microcapsule of claim 70, wherein said adjuvant 
further comprises an immunoglobulin, peptide, protein, 
hydrocolloid or polysaccharide. 
72. The microcapsule of claim 71, wherein said peptide or 
said protein selectively adheres to a target cell, tissue or 
tumor. 
73. The microcapsule of claim 71, wherein said hydro- 
colloid is selected from the group of such hydrocolloids 
consisting of collagen, isoelectric gelatin, agar, gum arabic, 
gum tragacanth,  carboxymethylcellulose (CMS), 
carboxymethyliethyl cellulose (CMEC), hydroxyethylcellu- 
lose (HEC), hydroxymethyliethyl cellulose (HMEC), 
hydroxypropyl cellulose (HPC), and carrageenans. 
74. The microcapsule of claim 68, wherein said third layer 
further comprises a surface active agent. 
75. The microcapsule of claim 44 wherein one or more of 
said layers further comprise fluorescent molecules selected 
from the group of fluorescent molecules consisting of 
fluoresceins, cyanins, naturally fluorescent molecules, and 
rhodamines. 
76. The microcapsule of claim 44 formed under micro- 
gravity. 
77. The microcapsule of claim 76 wherein said micro- 
gravity is at least 1.0 minutes in duration. 
78. The microcapsule of claim 44 formed below ambient 
temperature. 
79. The microcapsule of claim 44 comprising layers at 
least initially substantially balanced as to specific gravity 
between said layers. 
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80. A multi-layered microcapsule, comprising: 
a first layer comprising an organic solvent selected from 
the group of organic solvents consisting of methyl 
alcohol, ethyl alcohol and isopropyl alcohol, a first 
microcapsule layer-forming compound soluble in said 
first phase selected from the group consisting of glyc- 
erol monosterate, glycerol monooleate, glycerol 
monolaurate, glycerol dioleate, glycerol distearate, 
cholesterol, stigmasterol, phytosterol, campesterol, and 
lecithins, a co-solvent selected from the group of 
co-so lvents  cons is t ing  of C,-C, a lcohols ,  
t e t r a h y d r o f u r a n ,  d i o x a n e ,  a c e t o n i t r i l e ,  
dimethylformamide, dimethylacetamide, and dimethyl 
sulfoxide, oil selected from the group of oils consisting 
of poppy seed oil, olive oil, peanut oil, sesame oil, 
cotton seed oil, soybean oil, safflower oil, corn oil, 
sunflower seed oil, canola oil, mineral oil, a C,,-C,, 
paraffinic oil, liquid petrolatum, and water; 
a second layer immiscible with said first layer, said second 
layer comprising water, a second microcapsule layer- 
forming compound soluble in said second phase 
s e l e c t e d  f r o m  t h e  g r o u p  c o n s i s t i n g  of  
polyethyleneglycol, dextran polyvinylpyrrolidone, 
polyvinyl alcohols,  gelatin,  gum tragacanth,  
carrageenan, Karaya gum, Guar gum, gum arabic, 
2s alginates, carboxymethyl cellulose, hydroxypropyl 
cellulose, carboxypropyl cellulose, and lecithins, a sur- 
face active agent sorbitan monooleate treated with 
ethylene oxide, dextran, polyethylene glycol, C,,-C,, 
fatty acids, 2-amino-2-methyl-1-propyl aminomethyl 
propanol, amphoteric salts, and quaternary ammonium 
salts, and a salt selected from the group of salts 
consisting of NaC1, KC1, CaCl,, MgCl,, quaternary 
ammonium salts, cetyl trimethylammonium bromide, 
and 4-methoxy-4(3-phosphatidyl choline)spiro(l,2- 
dioxetane-3-g,l-adamantane) disodium salt; 
said surface active agent having a hydrophilicilipophilic 
balance value greater than that of said first microcap- 
sule layer-forming compound; and, 
said second microcapsule layer-forming compound hav- 
ing a hydrophilicilipophilic balance value lower than 
that of said surface active agent. 
81. The microcapsule of claim 58 further comprising at 
least two different pharmaceuticals, a first pharmaceutical in 
said first phase and a second pharmaceutical in said second 
phase. 
82. The microcapsule of claim 44 further comprising a 
radiopaque contrast agent. 
83. The microcapsule of claim 44 further comprising a 
magnetic resonance contrast agent. 
84. The microcapsule of claim 83 wherein said contrast 
SO agent is selected from the group of metallo-organic com- 
pounds consisting of ferrous gluconate, Gadolinium dieth- 
ylenetriamine pentaacetic acid, and iron pentacarbonyl. 
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